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Abstract 
 
Bovine viral diarrhea virus (BVDV) has emerged as one of the most important infectious 
diseases in cattle.  One particular important manifestation, after successfully establishing an in 
utero infection of the fetus during the first trimester, is the development of a persistently-infected 
BVDV (PI-BVDV) calf.  Persistently infected BVDV animals are a continuous source of virus 
and can shed the virus in virtually all secretions and excretions, including nasal discharges, 
saliva, semen, urine, tears, milk, and, to a lesser extent, feces.  The objectives of this research 
were to determine: 1) the effects of short term exposure (13  18 days on feed (DOF)) to PI-
BVDV feeder cattle; 2) the outcome of testing and removing PI-BVDV feeder calves at time of 
feedlot arrival on health, performance, and carcass characteristics; 3) the survival of BVDV on 
materials associated with livestock production; and 4) characterization of testing and longitudinal 
prevalences for PI-BVDV beef cattle.  Testing and removing PI-BVDV calves at 13 to 18 DOF 
was too late to remove a morbidity effect due to PI-BVDV exposure.  However, mortality, 
performance, and carcass characteristics were not different in cattle exposed to PI-BVDV cattle.  
Additionally, there were no harmful outcomes when newly arrived feeder cattle were exposed to 
a PI-BVDV animal for one to two days following feedlot entry. A non-cytopathic, Type 1b, 
BVDV was capable of surviving after application to various materials used in livestock 
production.  BVDV tended to survive longer on non-porous materials than porous materials.  
When in the presence of mucus, BVDV was protected from degradation for longer periods of 
time than when not in the presence of mucus.  There was no difference in overall PI-BVDV 
prevalence within cattle sampled in 2006 and 2007. Cattle that weighed less than 300 lbs. had a 
greater likelihood of being PI-positive than cattle with increased weights.  Several months of the 
year had a greater likelihood of having PI-positive animals.  Based on operation, cow-calf and 
  
stocker operations had a greater likelihood of having PI-positive animals than did feedlot 
operations.  
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Abstract 
Bovine viral diarrhea virus (BVDV) has emerged as one of the most important infectious 
diseases in cattle.  One particular important manifestation, after successfully establishing an in 
utero infection in the fetus during the first trimester, is the development of a persistently-infected 
BVDV (PI-BVDV) calf.  Persistently infected BVDV animals are a continuous source of virus 
and can shed the virus in virtually all secretions and excretions, including nasal discharges, 
saliva, semen, urine, tears, milk, and, to a lesser extent, feces.  The objectives of this research 
were to determine: 1) the effects of short term exposure (14  18 days on feed (DOF)) to PI-
BVDV feeder cattle; 2) the outcome of testing and removing PI-BVDV feeder calves at time of 
feedlot arrival on health, performance, and carcass characteristics; 3) the survival of BVDV on 
materials associated with livestock production; and 4) characterization of testing and longitudinal 
prevalences for PI-BVDV beef cattle.  Testing and removing PI-BVDV calves at 14 to 18 DOF 
was too late to remove a morbidity effect due to PI-BVDV exposure.  However, mortality, 
performance, and carcass characteristics were not different in cattle exposed to PI-BVDV cattle.  
Additionally, there were no harmful outcomes when newly arrived feeder cattle were exposed to 
a PI-BVDV animal for one to two days following feedlot entry. A non-cytopathic, Type 1b, 
BVDV was capable of surviving after application to various materials used in livestock 
production.  BVDV tended to survive longer on non-porous materials than porous materials.  
When in the presence of mucus, BVDV was protected from degradation for longer periods of 
time than when not in the presence of mucus.  There was no difference in overall PI-BVDV 
prevalence within cattle sampled in 2006 and 2007. Cattle that weighed less than 300 lbs. had a 
greater likelihood of being PI-positive than cattle with increased weights.  Several months of the 
  
year had a greater likelihood of having PI-positive animals.  Based on operation, cow-calf and 
stocker operations had a greater likelihood of having PI-positive animals than did feedlot 
operations.  
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CHAPTER 1  LITERATURE REVIEW 
Pestivirus 
Bovine viral diarrhea virus (BVDV) is a member of the genus Pestivirus within the 
family Flaviviridae, which also contains the genera Flavivirus and Hepacivirus (Brock et al., 
1992).  Other members of the genus are the important animal pathogens Classical swine fever 
virus and Border disease virus of sheep.  Pestiviruses are enveloped, single stranded, positive-
sense RNA viruses with genomes of ~12.3 kb that contain one long open reading frame (ORF) 
coding for a polyprotein of about 4,000 amino acids, which is co- and post-translationally 
processed into at least 12 mature proteins (Lackner et al, 2004; Lindenbach et al, 2001).  The 
proteins C, Erns, E1, and E2 are structural components of the virion.  Additionally, the Erns and 
E2 proteins induce neutralizing antibodies in infected animals and elicit protective immunity 
(Rumenapf et al, 1993). 
Cytopathic (cp) and noncytopathic (ncp) biotypes of all pestivirus species can be 
differentiated during replication in tissue culture systems.  The cp phenotype is characterized by 
a loss of control of genome replication and reduced ability of the infected cell to prevent a type 1 
interferon (IFN) response to double stranded RNA (dsRNA).  The genome of the pestitviruses 
are similar to human hepatitis C virus, in that they both have a similar gene expression, 
biochemical properties and similar functions for the viral proteins.  A few differences do exist, 
one of which is the coding of two additional proteins by the pestivirus RNA.  The two extra 
proteins are the Npro and Erns.  The Npro is a protease which interferes with the host interferon 
(IFN) response, which is critical for anti-viral effectiveness.  The Erns has a dual purpose 
function; it is an important component of the viral envelope and it has intrinsic RNase activity.  
The Erns is also secreted into the extracellular spaces. Deletion of the Npro causes attenuation, 
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whereas deletion of the Erns allows viral replication to occur, but there is no infectious virus 
produced. 
Bovine Viral Diarrhea Virus 
In 1946, bovine viral diarrhea (BVD) was first reported, but it took another several years 
to identify the responsible virus, which was designated bovine viral diarrhea virus (BVDV) 
(Olafson et al, 1946; Baker et al, 1954; Pritchard et al, 1955; Underdahl et al. 1957).  There are 
two genotypes of BVDV, type 1 and type 2, and their nucleotide sequence homology is roughly 
60% similar.  Within type 1 there are eleven subgenotypes; however, type 1a and 1b are the most 
prevalent.  Within type 2 there are two subgenotypes, type 2a and 2b (Ridpath et al. 1994).   In 
addition to classification by subgenotype, BVDV is also classified by biotype.  The biotype 
classifications for BVDV are noncytopathic (ncp) and cytopathic (cp).  The characterization is 
based on the presence or absence of cytopathic effect in cell culture systems (Qu et al, 2001).   
Noncytopathic biotypes are more prevalent in nature and are believed to be the origin of 
cytopathic strains. 
Clinical Symptoms of BVDV 
The clinical manifestations of BVDV are diverse and vary in severity, duration, and the 
organ system involved.  In cattle seronegative and immunocompetent to BVDV, the majority of 
BVDV infections are subclinical.  It has been estimated that 70 to 90 % of BVDV infections 
occur without clinical manifestations (Ames, 1986).   After infection, the upper respiratory tract 
and lymphoid tissue are sites for viral replication (Bolin, 1990).  Cattle undergoing subclinical 
infection may demonstrate a mild elevation in body temperature and leukopenia. Subclinical 
BVDV infections are likely the reason for the high prevalence of seropositive cattle (Harkness et 
al, 1978).  
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As the infection becomes clinical, the name transitions to bovine viral diarrhea (BVD). 
Typically animals are 6 months to 1 year of age when clinical disease presents, which is 
characterized by high morbidity and low mortality.  The incubation period is 5 to 7 days and is 
followed by transient fever and leukopenia.  Viremia occurs 4 to 5 days after infection and can 
persist for up to 15 days (Brownlie et al, 1987; Duffell et al, 1985).  Clinical findings include 
depression, anorexia, oculonasal discharge, occasionally oral lesions characterized by erosions 
and ulcerations, diarrhea, and a decrease in milk production.   
Given that BVDV is an RNA virus, the genomic diversity creates some strains that are 
more pathogenic to the host than others.  Infection with a type 2 BVDV is usually more severe 
than a type 1 BVDV.  Many of the clinical signs are similar for type 1 and type 2 BVDV; 
however, one difference for type 2 BVDV is the development of thrombocytopenia during an 
infection (Nagele, 1984).  Furthermore, noncytopathic BVDV strains are more commonly 
associated with thrombocytopenia.   The clinical consequence of thrombocytopenia is bloody 
diarrhea, epistaxis, petechial and ecchymotic hemorrhages on mucous membranes, and bleeding 
from injection site (Rebhun et al, 1989).   
In the early 1990s there were several reports of an increase in the severity of acute 
clinical cases of BVDV.  These clinical cases where associated with an acute onset of diarrhea, 
pyrexia, decreased milk production, morbidity near 40 % and mortality ranged between 10 to 25 
% (David et al, 1994; Hibberd et al, 1993; Carmen et al, 1994).  Many of the viral isolates were 
noncytopathic and were typed as a type 2 BVDV.  Interestingly, during the time frame that these 
severe acute BVDV cases where occurring, commercial BVDV vaccines only contained a type 1 
BVDV.  Serologic data has suggested that there is relatively low cross reactivity between type 1 
and type 2 BVDV (Pellerin et al, 1994).  In light of this, there were concerns about the sufficient 
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cross protection from type 1 BVDV vaccines.  However, a BVDV type 1 modified live vaccine 
given to 2-week old calves protected them from a later challenge with a type 2 BVDV (Ellis et 
al, 2001). 
BVDV Immunosuppression 
 It has been well established that acute BVDV infections can result in immunosuppression 
of the host (Potgieter, 1988).  The important aspects of BVDV induced immunosuppression is 
that the hosts susceptibility to other pathogens is increased and the pathogenicity of co-infecting 
pathogens may also be enhanced.  The ability of BVDV to cause immunosuppression contributes 
to a broad range of clinical diseases (Baker, 1995). 
BVDV and Bovine Respiratory Disease  
The majority of evidence is suggestive of a role for BVDV in bovine respiratory disease 
(BRD).  In one study, BVDV was the virus most often demonstrated from pneumonic lungs of 
feedlot cattle and usually was found in association with Mannheimia haemolytica (Reggiardo, 
1979).  Additionally, an association between BVDV antibody titers and treatment for BRD has 
been reported (Martin et al, 1986).  
BVDV Infections in Immunocompetent, Pregnant Cattle 
 In addition to the typical clinical manifestations of BVD described earlier, transplacental 
transmission to the conceptus is possible in cattle (Duffell et al, 1985).  The principle 
determinant of the outcome of fetal infection is the gestational age at the time transplacental 
infection occurs.  Although one outcome of BVDV infection of pregnant cattle is the 
development of an immunotolerant calf, infection of pregnant cattle also has other outcomes.  If 
infected at the time of conception, there are reduced conception rates.  Also, within the first 4 
months of gestation, there is the potential for embryonic resorption, abortion, or growth 
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retardation.  Infections that occur at 4 to 6 months of gestations are associated with central 
nervous system disorders and congenital malformations.  Fetal mummification, premature birth, 
stillbirth, and weak calves can also occur.  Both cytopathic and noncytopathic biotypes can cause 
fetal infections and fetal loss; however, the noncytopathic biotype is more common (Dubovi et 
al, 1992).  Additionally, it is the noncytopathic biotype that produces immunotolerant 
persistently infected BVDV animals (McClurkin et al, 1984).   
Mucosal disease is a highly fatal form of BVD, which may be acute or chronic and is 
seen most frequently in persistently infected cattle.  The disease develops when a cytopathic 
BVDV, which is often an escape mutant from the animals own noncytopathic BVDV from the 
fetal infection, is antigenically similar to the noncytopathic internal BVDV.  Since the individual 
is immunotolerant to the ncp BVDV, the individuals immune system does not recognize the 
external cp BVDV.   It is also possible for mucosal disease to occur with an external cp BVDV 
(i.e. non-mutated ncp BVDVs); this can be discriminated by serology as these animals will have 
a serum titer to BVDV. 
Persistent Infection 
In the field, pestiviruses establish persistent infections in their natural hosts.  BVDV is a 
successful pathogen that can cause a persistent infection.  Approximately 0.5 to 2 % of newborn 
calves in dairy herds are persistently infected (Houe, 2003).  The early period of gestation is 
essential because if the fetus is infected later in the gestational period the fetus can use the 
adaptive immune system to eliminate the BVDV infection.    
Fetuses that survive infection with noncytopathic BVDV between 18 and 125 days of 
gestation are at significant risk for developing immunotolerance to the virus and subsequently 
become persistently infected (PI) with BVDV.  The first published account of a PI-BVDV 
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animal was in 1978 (Coria et al, 1978).  In that paper, Coria et al. described the isolation of 
BVDV from an animal that was seronegative to BVDV.  In light of these findings, they sought to 
answer how and under what circumstances this infection could have taken place.  They 
completed five experiments using five different BVDV isolates: 1) Two BVDV isolates (7443 
(ncp) & NY-1 (ncp)) were inoculated into seventeen fetuses of BVDV seropositive cows at 58 to 
125 days of gestation; and 2) Three BVDV isolates (VM (ncp), MC (ncp cp), and NADL (cp)) 
were inoculated intravenously into 44 BVDV seronegative cows at 42 to 144 days of gestation.   
The results indicated that the birth of calves PI with BVDV can result from exposure of a BVDV 
negative dam to BVDV between 42 and 125 days of gestation.  Interestingly, the use of the cp 
BVDV NADL-isolate did not cause a calf to be PI with BVDV; however, the use of a ncp 
BVDV isolate did cause calves to be PI with BVDV (McClurkin et al, 1984).  This was the first 
formal recognition that ncp isolates were able to induce immunotolerance during a specific 
gestational timeline. 
Infection of cells with viruses induces the production of interferons.  The inteferons 
associated with anti-viral effects are interferon-α (IFN-α), and interferon-β (IFN-β).  Interferons 
are induced by double stranded RNA (dsRNA), which is not found in mammalian cells, but is an 
important part of the genomes of some viruses.  Interferon-α and IFN-β have three major 
functions: 1) They induce resistance to viral replication by upregulating expression of proteins 
that destroy messenger RNA (mRNA) and inhibit downstream translation of viral proteins; 2) 
They induce the expression of major histocompatibility complex class 1 (MHC class 1) and 
make virally infected cells more recognizable to cytotoxic killing by CD8+ T-cells; and 3) They 
activate natural killer (NK) cells, which then kill virally infected cells. 
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The exact mechanism(s) by which the noncytopathic isolates induce persistent infection 
is not clear.  To persist in an individual, BVDV must overcome the hosts immune response.  
The type 1 interferons (IFN), commonly referred to as alpha/beta interferons (IFN α/β), are an 
important cellular mechanism that are stimulated in response to viral infections.  If produced, 
they place the cell in an antiviral state.  It not only does this for its own cell, but it is secreted and 
can protect other cells against viral infection.  The downstream signal transduction following 
upregulation of IFN-α/β is prolific (Der et al., 1998).   The better characterized antiviral proteins 
induced by IFN-α/β are protein kinase PKR and 2, 5-oligoadenylate synthetase, which are both 
activated by dsRNA and Mx protein.  Since the induction of IFN-α/β is detrimental to viral 
propagation and survival, many viruses have developed mechanisms to avoid the establishment 
of the antiviral state afforded by upregulation of IFN-α/β.  For example: 1) Some viruses prevent 
the induction of IFN synthesis; 2) Some viruses prevent the action of IFN after production; 3) 
Some interfere with signal transduction pathways activated after IFN binds its cellular receptor; 
and 4) Many viruses inhibit the activity of IFN-induced antiviral proteins (Schweizer et al, 
2006).   
Several laboratories have attempted to better understand the interplay between cp and ncp 
BVDV isolates with the immune system.  Cells infected with ncp BVDV do not undergo 
apoptosis, which is commonly referred to as programmed cell death (Adler et al, 1997; Perler et 
al, 2000; Schweizer et al, 1999; Zhang et al, 1996).  However, if a cell is infected first with a ncp 
BVDV and later infected with another virus, the cell will undergo apoptosis (Baigent SJ et al, 
2002; Schweizer et al, 2001).  Through the use of extensive in vitro systems, it has been shown 
that ncp BVDV inhibits the production of IFN (Adler et al, 1997; Perler et al, 2000; Schweizer et 
al, 2001).  This important in vitro finding has been confirmed using an in vivo BVDV model 
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(Charleston et al., 2001).  In that study, fetuses that were challenged with a non-cytopathic 
isolate failed to mount an IFN response and subsequently developed a persistent infection.  
While being resistant to induction of IFN, cells infected with ncp BVDV are capable of 
responding to exogenous IFN with a robust antiviral state that protects from infection with 
unrelated viruses without eliminating the ncp BVDV residing in the same cell (Schweizer et al, 
2001).  There have been several experiments completed to better understand the defects of the 
immune system with regards to recognition and clearance of homologous BVDV in PI-BVDV 
calves.  Interestingly, antigen presenting cells (APC) from a PI animal could stimulate a T-cell 
response to homologous virus.  To the researchers, this demonstrated that the mechanism 
associated with persistence did not involve antigen presentation (Glew et al, 2001). 
Laboratory Diagnosis 
There are several testing methodologies available to assist in diagnosing BVDV; 
however, not all methodologies are applicable to all clinical situations. For instance, the testing 
of acute infections manifested with clinical disease, reproductive failure, detection and 
elimination of PI individuals, testing for vaccine efficacy, biological products which require 
quality control and genotyping are situations where the testing methodology is important (Saliki 
et al, 2004).   
 There are a number of diagnostic tests available to the practitioner.  The gold standard is 
virus isolation.  A number of clinical specimens can be submitted for virus isolation.  Frequently, 
the clinical specimen will be a tissue or a serum specimen.  The clinical specimen with greatest 
opportunity for diagnosis is the white blood cell fraction from a whole blood sample.   When 
tissues must be used for virus isolation, the lymphoid organs, such as spleen, Peyers patch, 
mesenteric lymph nodes, and thymus are the most appropriate.   The use of serum can be 
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associated with variable results due to the potential presence of neutralizing antibodies.   After 
processing, an aliquot of the specimen is transferred into a cell culture system.  The most 
commonly used cell lines for virus isolation of BVDV are Mandin Darby Bovine Kidney 
(MDBK) cells, bovine turbinate (BT) cells, and bovine testicle (Btest) cells.   After a range of 
incubation times, typically 3  5 days, the cells are visualized to determine if they are infected 
with BVDV.  Cytopathic strains are easy to identify due to the destruction of the monolayer of 
cells.  On the other hand, a non-cytopathic strain will have a normal monolayer.  Therefore, it is 
necessary to use a monoclonal antibody with specificity for identification and confirmation of 
BVDV.  
 A cheaper and faster detection time can be accomplished by detection of BVDV antigen.   
One concern with antigen detection is a lack of sensitivity and reliability when compared to virus 
isolation.  Therefore, antigen detection methods are most often used for screening animals.  
Currently, there are three testing options: antigen capture enzyme linked immunosorbent assay 
(ACE); immunologic staining of fresh or formalin fixed tissues; and PCR.  As these tests are 
used as screening tools, they are employed for the identification of PI animals.  One limitation is 
that the tests may not differentiate an animal with an acute infection from a PI animal.  
Immunologic staining includes tissues samples, with probably the majority of the tests performed 
on ear notch biopsies. 
 With the advent of polymerase chain reactions (PCR), a number of valid PCR tests have 
been developed by a variety of testing centers.  Given that BVDV is an RNA virus, the PCR 
technology most commonly employed is reverse transcriptase PCR (RT-PCR).    Most samples 
can be used for RNA isolation; however, formalin fixed tissues can be an issue.  In one study, 
when BVDV infected tissues where held in 10 % formalin for 10 days, there was a loss of 
10 
 
detection.   If 5 % formalin was used, it extended the shelf-life to 3 months.  One limitation of 
PCR is a high cost.  To reduce the costs of PCR testing, pooling of samples is often allowed.   
Pooling is often used for serum samples and for bulk tank testing to identify the presence of a PI 
animal.  Another advancement in PCR technology is the development of real time PCR (rtPCR).  
Real time PCR takes advantage of molecular beacons that have a fluorescence tag which emits 
when they are cleaved by Taq polymerase.  In addition to the two standard 5 and 3 primers, an 
additional primer is developed that is labeled with a flurochrome.  The additional primer 
corresponds to an area between the 5 and 3 primers.  If the target is present in the sample, all 
the primers will bind to the DNA.  As the Taq polymerase adds the nucleotides to create the 
complementary DNA, it cleaves the flurochrome present on the additional primer and the 
flurochrome is released into the rtPCR solution.  This flurochrome is then measured with a 
spectrophotometer and graphed.  This technology allows for not only identification, but also for 
quantification of the number of viral transcripts. 
Serology is used for the measurement of antibody response in animals with natural 
exposure or after vaccination.  Two common testing methods are ELISA and serum 
neutralization.  ELISA is the less preferred of the two tests largely due to viral diversity.  On the 
other hand, the use of a serum neutralization assay is not without pitfalls.  Serum neutralization, 
which provides a titer of antibody, is subject to variation by the strain of BVDV that is used and 
the test cells.  Lastly, because of a lack of standardization across diagnostics laboratories, not all 
diagnostic laboratories use the same BVDV and/or cells.  Therefore, there is the chance that 
there can be a discrepancy between testing laboratories.  The strengths of the serum 
neutralization assay, when applied appropriately, are to: 1) assess vaccine efficacy; 2) assess 
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vaccination protocol compliance; 3) assess herd status as to exposure to BVDV; and 4) associate 
BVDV with clinical signs. 
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CHAPTER 2 - Effects of Short Term Exposure of Feeder Cattle to 
Calves Persistently Infected with Bovine Viral Diarrhea Virus 
ABSTRACT 
A research trial involving auction derived feeder steers and heifers (n = 2,954) was 
conducted at a single commercial feedlot in Kansas to determine the effects of testing  cattle 
persistently infected (PI) with bovine viral diarrhea virus (BVDV) at revaccination (10  14 days 
on feed (DOF)) and removing them (13  18 DOF) from the home pen.   After removal of test 
positive animals, the effect of the short term exposure (STE) on the health, performance and 
carcass characteristics was determined. The percentage of calves exhibiting signs of morbidity 
was increased in cattle with STE to PI-BVDV (P < .01).  Cattle that had no exposure (NE) to PI-
BVDV calves had a morbidity of 19 % compared to a 30 % morbidity rate observed in pens with 
STE to a PI-BVDV calves during the feeding period (P < .01)  Further characterization of the 
temporal pen morbidity of STE and NE revealed that 31.7 % of all STE and 15.3 % of NE pulls 
occurred during 0 - 7 DOF.   Additionally, the incidence of cattle treated for Bovine Respiratory 
Disease (BRD) in STE calves was 2.17 initial treatments per 1,000 head-days at risk (95% CI 
1.73 to 2.72) whereas the incidence of treatment in NE was 1.28  initial treatments per 1,000 
head-days at risk (95% CI 0.98 to 1.68).  Short term exposure to PI-BVDV had no effect on the 
retreatment rate (P = .82), death loss (P = .69), or performance (P > .05).  There was no evidence 
of a BVD PI exposure x sex interaction (P = .62) for carcasses that graded choice or better, but 
there was a main effect of sex (P < .01).  There was evidence of a BVD-PI exposure x sex 
interaction for Yield grade 2 or greater carcasses (P=.03).  Testing at 10 - 14 DOF was too late in 
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the feeding period to eliminate the observed initial morbidity spike that occurred during 0  7 
DOF which resulted in the overall morbidity differences between calves with STE or NE.  
 
INTRODUCTION 
Infection with bovine viral diarrhea virus (BVDV) contributes to a variety of 
economically important disease syndromes in beef cattle, including bovine respiratory tract 
disease and immunosuppression of stocker and feedlot cattle 3.  The outcome of BVDV fetal 
infections in susceptible heifers and cows is dependent on the age of the fetus when exposed.  
Infection can result in abortion, stillbirths, congenital malformations and birth of persistently 
infected (PI) calves.  Persistent infection in a calf develops when a susceptible heifer or cow is 
exposed to a noncytopathic BVDV during pregnancy at approximately 45 to 125 days of 
gestation5.  Cattle persistently infected with BVDV can shed copious amounts of BVDV into the 
environment through secretions and excretions, including nasal discharges, saliva, semen, urine, 
tears, and to a lesser extent, feces. 
Relatively few cattle are PI on arrival at a feedlot.  The prevalence of PI-BVDV feeder 
cattle entering feedlots is estimated to be 0.3 % 4.  PI cattle are important sources of virus for 
animals in direct or close contact.  In a recent study, the risk of initial treatment for bovine 
respiratory disease (BRD) was 43 % greater in cattle exposed to a PI calf 5.  Persistently infected 
calves tend to have lower growth rates and often die from classic mucosal disease or other 
diseases during the feeding period 10.    
Given the increased risk of morbidity associated with exposure to PI calves, it is 
important to understand the impact of identifying and removing these animals to limit their 
exposure to cattle and limit costs associated with treatment (labor and medicine).  Therefore, our 
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objective was to identify (10  14 days on feed (DOF)) and remove (13  18 DOF) positive PI-
BVDV feeder cattle to determine what effect short term exposure to PI-BVDV has on health, 
performance, and carcass characteristics of cattle within a pen that contained a PI animal.  
MATERIALS AND METHODS 
Cattle and sample collection 
Auction derived steers (n = 932) and heifers (n = 2,022) (total head = 2,954) arrived at a 
12,000 head capacity feedlot in Kansas between 8/24/05  11/15/05.  Upon arrival, the cattle 
were administered doramectina, a modified live vaccine containing bovine herpesvirus type 1, 
parainfluenza type 3, BVDV (Types 1 and 2) and bovine respiratory syncytial virusb.  In 
addition, a steroid implantc was administered subcutaneously in the caudal aspect of the ear.  
After initial processing, cattle were housed in 19 pens (range 52 - 255 head/pen) and managed in 
accordance with routine feedlot practices.   Ten to fourteen days after processing, the cattle 
received a second MLV vaccinationd and a multivalent clostridial vaccinee.  At revaccination, 
fresh skin (ear notch) specimens were collected and placed in phosphate buffered saline solution 
and tested for BVDV antigen by antigen capture ELISA (ACE).  During the feeding period, 
animals exhibiting symptoms consistent with respiratory disease were removed for diagnosis and 
treated with antimicrobials if necessary.  The first, second, and third antimicrobial treatments for 
BRD were tulathromycinf (Draxxin, Pfizer Animal Health), florfenicolg (Nuflor, Schering 
Plough Animal Health), and ceftiofur hydrochlorideh (Excenel, Pfizer Animal Health), 
respectively.   
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Antigen Capture ELISA 
Detection of BVDV antigen in skin specimens (ear notch) was performed by use of a 
commercial antigen capture ELISA (ACE) kiti.  Results were calculated by the following 
equation: standardized OD = (raw OD of sample  raw OD of negative control)/(raw OD of 
positive control  raw OD of negative control).  Samples with standardized OD values < 0.20 
were considered negative, and those with OD values > 0.39 were considered positive.  Samples 
with values from 0.2 to 0.39 were retested with detector reagents with or without antibody.  If an 
animal tested positive at revaccination, it was removed from the pen, isolated, and retested 21 
days later by immunohistochemistry (IHC) on an ear notch biopsy for BVDV for confirmation of 
PI status.  
 
Treatment Groups 
If an animal tested positive for BVDV by ACE, it was removed from the home pen 
(range = 13  18 DOF).  Twenty one days after the original ACE test, confirmation of ACE 
positive animals was performed with IHC.  After confirmation of BVDV PI positive status, the 
home pen of origin was considered to have had short-term exposure (STE) to PI-BVDV animals.  
Pens with STE were compared to pens that had no exposure (NE) to PI-BVDV.  Short term 
exposure and NE pens were followed through closeout and slaughter.  
 
Health and Performance Data 
Feedlot data were collected from electronic records maintained at the feedlot.   Data 
obtained from the close-out sheets included initial weight, final weight, days on feed, average 
daily gain, dry matter intake, feed to gain, and feed cost of gain per pound.   Health data were 
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recorded daily by trained feedlot personnel.  Data gathered from the animal health computerj 
included respiratory morbidity, number of treatments, death loss and treatment costs. 
 
Statistical Analysis 
Data were analyzed using commercially available statistical analysis softwarek.  Pen-level 
response variables were generated and analyzed using regression techniques.  Continuous 
response variables were analyzed using general linear models whereas discrete binomial 
response variables (events/trials) were analyzed using generalized linear models with a logit link 
function.  The interaction of exposure and sex was evaluated, and, if not significant, removed 
from the model.  Further, if the main effect of sex was not significant, it too was removed from 
the model while the main effect of exposure was forced into the model.  A time by exposure 
effect on counts of initial treatment was evaluated using negative binomial models and repeated 
measures methodologies in that within-pen dependency over time was modeled using 
compound-symmetry matrices.  Model predicted estimates of incidence of initial treatment for 
respiratory disease and associated confidence intervals were calculated from the final model.   
 
RESULTS 
Of the 2,954 head that were tested for PI-BVDV, 10 calves were positive (prevalence = 
0.35%).  At the pen level, 5 of the 19 pens had exposure to a PI-BVDV calf (26.3%).  The 
percentage of calves exhibiting signs of morbidity was increased in animals with short term 
exposure (STE) to PI-BVDV (P = .01; Table 2.1).  The temporal pattern of morbidity was 
investigated.  Cattle in the STE pens had increased morbidity relative to the cattle in the NE pens 
during the first seven days on feed (Figure 2.1).  There was no evidence of a BVD PI exposure x 
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period interaction (P = 0.25), but there was a main effect of BVD PI exposure on morbidity rates 
(P=0.02).  The incidence of BRD treatments in STE cattle was 2.17  initial treatments per 1,000 
head-days at risk (95% CI 1.73 to 2.72) whereas the incidence of BRD treatments in NE cattle 
was 1.28 initial treatments per 1,000 head-days at risk [95% CI 0.98 to 1.68 (Figure 2.2)].  Short 
term exposure to PI-BVDV calves had no effect on the percentage of calves that were retreated 
(P= .82).  Additionally, STE cattle had similar death loss relative to NE cattle (P= .63).   
A BVD PI exposure x sex interaction was observed for the final weight of finished cattle.  
Upon further examination, heifers with no exposure to a PI-BVDV animal had an increased final 
weight compared to heifers with STE to a PI-BVDV animal.  Steers with STE to a PI-BVDV had 
heavier final weights than steers with no exposure.  This is attributed to the finding that steers 
with STE were fed on average 22 days longer than animals with no exposure.  Therefore, the 
main effects of STE or NE to a PI BVDV animal are presented.   
Average daily gain was similar in STE calves relative to NE calves (P= 0.34; Table 2.2).  
Also, during the feeding period, daily dry matter intake (DMI) was similar in the STE calves 
relative to cattle never exposed to a PI-BVDV calf (P= .33).  There was no difference in the feed 
to gain ratio (F:G) (P= .57) between the two BVDV exposure groups.  No difference was found 
in the cost of gain for calves regardless of BVDV exposure was observed (P= .24).  There was no 
evidence of a BVD PI exposure*sex interaction (P = .62) for carcasses that graded choice or 
better, but there was a main effect of sex (P < 0.0001).  There was evidence of a BVD PI 
exposure*sex interaction for yield grade 2 or greater carcasses (P=.03). 
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DISCUSSION 
The current study was conducted to measure the effects of testing and removal of PI-
BVDV feeder cattle after arrival in the feedyard.  Based on the morbidity results, testing at 10 -
14 days on feed was too late in the feeding period to eliminate the observed initial morbidity 
spike that occurred during 0  7 DOF.  Short term exposure to PI-BVDV had no effect on 
retreatment rate, death loss, performance or carcass characteristics.   
Nineteen percent of the NE cattle and 30 % of STE cattle exhibited morbidity during the 
feeding period.  This is different than other published reports 4, 7.  Loneragan et al. observed that 
there was no difference in morbidity rate for cattle within a pen that contained a PI animal and 
those pens that did not contain a PI animal 4.  In a second analysis by Loneragan et al., morbidity 
was defined more broadly to include those cattle considered exposed in the first analysis and 
those cattle in pens adjacent to a pen containing a PI animal.  From their second analysis, cattle 
exposed to a PI animal had a 43% greater risk of treatment for respiratory disease 4.  
 In the study reported here, short term exposure to a PI-BVDV had no effect on 
performance.  This was an unexpected finding given the increased morbidity that was observed 
during 0  7 DOF, this has been repeatedly established as having an effect on animal 
performance.  A summary of results from the Texas A&M Ranch to Rail program (1992  1997) 
revealed that animals treated for health complications during the finishing period had 0.05  0.25 
kg lower ADG than their counterparts that were not treated 6.  Similar reductions in ADG in 
cattle treated for respiratory diseases has been reported elsewhere [Van Donkersgood et al. 1992 
(1.11 vs. 1.25 kg/d)] 11.  Additionally, Hutcheson et al. and Sowell et al. have reported that 
morbid cattle require increased time after arrival to begin consuming feed when compared to 
their healthy counterparts 2, 9.    
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A feedlot finishing study by Gardner et al. reported that steers treated for respiratory 
disease had lower final live weights, ADG, hot carcass weights, less external and internal fat, and 
more desirable yield grades.  Additionally, steers that were treated had a higher prevalence of 
carcasses that graded U.S. Standard than steers that were never treated1.  Similar results were 
reported in a feedlot-arrival modified live viral vaccine study in which morbidity was improved 
but there was no improvement in carcass characteristics8.  The results from the study indicated 
that there were no significant differences between the experimental groups in any of the carcass 
characteristic variables that were measured despite noting significant differences in morbidity 
between the treatments8. 
Clinical signs of BRDC and transient viral infections can present similarly in feeder 
cattle.  There is no mechanism in feedlot production settings for clinical differentiation of fever 
of unknown origin in feeder cattle.  Both the current study and the study by Schunicht were 
primarily looking at viral exposure and viral vaccination protocols.  It is conceivable to the 
authors of this paper, that transient viral infections might be less detrimental to the overall health 
and performance of cattle relative to exposure to bacterial pneumonia diseases.  Further 
classification of BRDC etiology and its effects on performance are justified. 
The total morbidity between the STE and NE groups was different.  Based on these data, 
11 % more cattle would be treated with antibiotics in 100 head pens containing a BVDV PI calf 
verses non-PI pen with similar head count.  In our study, tulathromycin was used as the first 
treatment for respiratory disease.  Considering the cost of tulathromycin ($3.45/cwt), the weight 
of the morbid calves (600 lbs.) and the extra number of head needing treatment (n=11), the cost 
for medicine alone is $228 greater than in the NE group.  If testing earlier removed this 
morbidity effect, there would have been a savings of $228/100 head or $2.28/head in medicine 
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costs alone.  The cost of testing to identify PI-BVDV animals may potentially be returned or 
offset by reducing the medicine costs alone.  Conceivably, testing and removing PI cattle prior 
to, or 1 to 2 days after arrival, may decrease the morbidity difference in pens exposed to PI 
animals to the level of non-PI pens.   
Testing and removing PI-BVDV calves at 13 to 18 days on feed was too late in the 
feeding period to remove a morbidity effect due to PI-BVDV exposure.  However, death loss, 
performance and carcass characteristics were not different in cattle exposed to PI-BVDV cattle 
compared to cattle never exposed.  Therefore, further characterization of the optimal time for 
testing and removal of PI-BVDV feeder cattle is needed to minimize morbidity for in-contact 
cattle.   
 
Endnote   
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Table 2.1.  Effect of short term exposure to persistently infected BVDV cattle on feeder     
calf morbidity and mortality.   
Item NE STE SEM P-value 
Morbidity (%) 18.8 29.6 5.4 <.01 
Retreat (%) 14.4 21.7 4.7 .82 
Mortality (%) 4.3 5.6 1.8 .69 
 
 
Table 2.2.  Effect of short term exposure to persistently infected BVDV cattle on feeder 
calf performance.   
Item NE STE SEM P-value
In wt., (lbs.) 626 599 30.2 .44 
Out wt., (lbs.) 1142 1163 16.2 .28 
DOF, (d) 197 219 11.4 .10 
ADG, (lb./d) 2.53 2.46 0.07 .34 
DMI, (lb./d) 16.4 15.7 0.68 .33 
FG, (lbs. feed/lb. of gain) 6.5 6.4 0.17 .57 
COG, ($/lb.) 60. .62 0.01 .24 
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Figure 2.1.  Temporal morbidity of feeder cattle with or without exposure to PI-BVDV.  
The percent of total respiratory morbidity (y-axis) that occurred during the feeding period 
was plotted against days on feed (x-axis).     
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Figure 2.2.  Epidemic curve for cohorts either exposed or not exposed to an animal PI 
with BVDV among feedlot cattle.  Exposure was defined to include cattle in a pen that 
contained a PI animal.  Data for the epidemic curve are number of initial treatments for 
respiratory tract disease per 1,000 head days at risk.  
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CHAPTER 3 - Testing and Removal of Feeder Calves Persistently 
Infected with Bovine Viral Diarrhea Virus at the Time of Feedlot 
Arrival and Outcome on Health, Performance and Carcass 
Characteristics 
ABSTRACT 
Twelve lots of auction derived steers totaling 1,577 head with an unknown health history 
(initial body weight 660 lb [300 kg]; 12 pens) were used to investigate testing and removal of 
feeder calves persistently-infected with bovine viral diarrhea virus (PI-BVDV) upon arrival at a 
single feedlot in central Kansas.  Pens with a PI-BVDV calf on arrival were considered exposed 
and were compared to pens without a PI-BVDV calf on arrival.  The exposed and non-exposed 
pens were followed from arrival through harvest to investigate the impact of exposure on health, 
performance, and carcass characteristics of feedlot cattle.  A significant difference in the 
morbidity between exposed (2.3%) and non-exposed (7.2%) cattle was found (P < 0.01).   No 
differences were found between the two groups for retreatment or mortality rates.  Exposure to a 
PI-BVDV individual for less than 48 hours after arrival did not have an effect on performance 
parameters (final body weight, days-on-feed, average daily gain, dry matter intake, gain to feed, 
or cost of gain).  There was an increased percentage of USDA yield grade 4 and 5 (P = 0.01) 
carcasses in the exposed group, but there were no other differences in carcass characteristics 
between groups. 
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INTRODUCTION 
Bovine viral diarrhea virus (BVDV) is an important pathogen of cattle, and infection can 
lead to a variety of adverse health outcomes such as enteritis, abortion, fetal malformations, and 
bovine respiratory disease (BRD).7  The outcome of BVDV fetal infections in susceptible heifers 
and cows is dependent on the age of the fetus when exposed.  Persistent infection in a calf 
develops when a susceptible fetus is exposed to a non-cytopathic BVDV during pregnancy at 
approximately 45 to 125 days of gestation.8  Persistently infected animals are a continuous 
source of virus and can shed the virus in virtually all secretions and excretions, including nasal 
discharges, saliva, semen, urine, tears, milk, and, to a lesser extent, feces.2,3,4,10  
 Prevalence of persistently infected (PI) BVDV feeder cattle entering feedlots is 
estimated to be 0.3%.7,12  During the feeding period, calves PI with BVDV tend to have lower 
growth rates and often die from mucosal disease.9  Although few cattle PI with BVDV arrive at 
feedlots, the risk of initial treatment for BRD was 43% greater in cattle exposed to a PI calf.7  
Given the potential negative impact of exposure to a calf PI with BVDV, it may be advantageous 
to test newly arrived cattle.  There are a number of tests available to practitioners; however, the 
BVDV antigen capture enzyme linked immunosorbent assay (ACE) is often used for the initial 
screening of feedlot cattle.  A number of sample handling practices have been evaluated and 
found to have little impact on test sensitivity and specificity of ACE testing for BVDV.6,11  
 Effects of testing and removing PI cattle at revaccination (10  14 days on feed) 
were determined in a previous study.12   No differences for mortality rates, retreatment rates, 
performance, or carcass characteristics were evident.  Morbidity rates were different between the 
non-exposed and exposed groups (19% for non-exposed vs. 30% for exposed).  Based on these 
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findings, this trial was conducted to assess the impact of testing and removing PI cattle within 
two days after arrival.   
 
 
MATERIALS AND METHODS 
Cattle and sample collection 
Twelve lots of auction-derived steers totaling 1,577 head with an unknown health history 
(initial BW 660 lb, ± 50.9; 299 kg ± 23.1) arrived at a commercial feedlot (one-time capacity of 
12,000 animals) in central Kansas between March 2006 and October 2006.  After arrival to the 
feedlot, cattle were placed in receiving pens and offered free choice hay and water.  Cattle were 
processed after being allowed one hour of rest for every one hour of transport to the feedlot.  All 
calves were processed within 24 hours of arrival.  At processing, animals received a unique 
identification tag, administered doramectin,a a steroid growth implant,c and a modified-live 
vaccine containing bovine herpesvirus type 1, parainfluenza type 3, BVDV (Types 1 and 2), and 
bovine respiratory syncytial virusb at arrival.  During initial processing, fresh skin (ear notch) 
specimens were collected and placed in phosphate buffered saline solution to be tested for 
BVDV antigen by ACE.   
After initial processing, cattle were housed in 12 pens (range 62-302 animals/pen) and 
managed in accordance with routine feedlot practices.   Ten to 14 days after initial processing the 
cattle received a second MLV vaccined and a multivalent clostridial bacterin-toxoid.e   
Animals that exhibited one or more clinical signs consistent with respiratory disease 
(depression, mucopurulent nasal discharge, increased respiratory rate and effort, and/or anorexia) 
were removed from the home pen for diagnosis.  Animals with a rectal temperature greater than 
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103.5°F (39.7°C) were treated with an antimicrobial.  Additionally, all cattle in the feedlot were 
tested for PI-BVDV and removed if determined to be positive.  All pens were maintained in 
accordance with standard feedlot practices.  The first, second, and third antimicrobial treatments 
for BRD were tulathromycin,f florfenicol,g and ceftiofur sodium,h respectively.   
 
Antigen Capture ELISA 
Detection of BVDV antigen in skin specimens (ear notch) was performed using a 
commercial ACE kit.i  Results were calculated by the following equation: standardized optical 
density (OD) = (raw OD of sample  raw OD of negative control)/(raw OD of positive control  
raw OD of negative control).  Samples with standardized OD values < 0.20 were considered 
negative, and those with OD values > 0.39 were considered positive.  Samples with values from 
0.2 to 0.39 were retested with detector reagents with or without antibody.  Upon secondary 
analysis, no animals had values from 0.20  0.39.  Animals that tested positive by antigen 
capture ELISA were removed from the pen, isolated, and retested 21 days later by 
immunohistochemistry (IHC) for confirmation of PI-BVDV status. 
 
Assignment to Treatment Groups 
All cattle that arrived at the feedlot were tested for PI-BVDV by ACE.  If an animal 
tested positive for BVDV using ACE testing, it was removed from the home pen (range = 1  2 
days-on-feed).  Not all the pens that were tested contained a PI-BVDV animal.  When an animal 
PI with BVDV was found in a pen, a pen with no PI-BVDV animals was identified.  This created 
a pair of pens to be followed over time.  Paired pens were similar with respect to initial weight, 
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date of arrival (same week), sex, and geographical origin.  After a pair of pens was enrolled, the 
exposed and NE pens were followed through closeout and harvest. 
 
Health and Performance Data 
Feedlot data were collected from electronic records maintained at the feedlot.   Data 
obtained from the closeout sheets included initial body weight (BW), final BW, days-on-feed, 
average daily gain (ADG), dry matter intake (DMI), gain to feed (G:F), and feed cost per pound 
of gain (COG).   Initial and final body weight was determined by the average weight of the lot at 
the time of arrival or harvest, respectively.  Health data were recorded daily by trained feedlot 
personnel.  The feedlot and pen riders were masked (blinded) from treatments.  Pens were 
harvested based on visual appraisal as well as targeted harvest dates.  Paired pens were harvested 
at approximately the same time (within the same week).  Data retrieved from the animal health 
computer systemj included respiratory morbidity rate, number of treatments, death loss, and 
treatment costs. 
 
Statistical Analysis 
Performance based data (ADG, DMI, initial BW, final BW, G:F, dressing percent, and 
COG) were analyzed as a single factor experiment using the general linear model of SAS release 
9.1.3.  Pen was the experimental unit.  Non-parametric data (morbidity rates, retreatment rates, 
mortality rates, quality grade, and yield grade) were tested as binomial proportions using the 
Glimmix procedures in SAS.  Percentages are reported in tables for animal health and carcass 
variables.  The largest standard error of the least squares means is reported in the tables.   
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RESULTS 
Five of the six pens that were considered positive on arrival had one PI animal on arrival.  
The sixth pen that was considered positive on arrival contained 4 PI animals.  Following a 
positive ACE test, PI animals were removed and fed.  The health and performance of the positive 
animals were not followed.  Animal health and feedlot performance data are in Tables 3.1 and 
3.2.  A significant difference in the morbidity between exposed (2.3%) and non-exposed (7.2%) 
cattle was found (P < 0.01).   There were no differences between groups for retreatment rate or 
mortality rate.  There were no differences in ADG (P ≥ 0.28), DMI, G:F or cost of gain between 
exposed and NE groups.  There were no differences in dressing percent (P = 0.55) or quality 
grade (P = 0.46) of carcasses from the exposed and NE groups (Table 3.3).  There were no 
differences for calculated yield grades 1 and 2 (P = 0.46) or yield grade 3 (P = 0.26) between 
different BVDV exposure groups of cattle; however, percentage of carcasses with a calculated 
yield grade of 4 and 5 was higher in cattle exposed to BVDV (P = 0.01). 
 
DISCUSSION 
In this study, cattle with no exposure to PI calves early in the receiving period had higher 
morbidity rates than the cattle exposed to a PI calf; however, morbidity rates for both groups of 
cattle were less than 8% (Table 3.1).  In a previous study conducted at this facility, cattle with 
short-term exposure to a PI animal (tested at d 10  14 and removed d 13  18) had higher 
morbidity rates than cattle with no exposure (30% vs. 19%, respectively).12  In a large pen study, 
Loneragan et al found that cattle within a pen that contained a PI animal were at slightly greater 
risk of BRD than non-exposed cattle(7.36% vs. 5.14%).  A more profound impact was found 
when adjacent pens were included in their analysis.  When adjacent pens were included in the 
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analysis, the incidence of treatment for respiratory disease was 43% greater.7  In another large 
pen study, Booker et al found no difference in the respiratory morbidity rate of cattle in pens that 
contained a PI individual compared to those housed in pens without a PI animal; however, they 
were not able to evaluate the health of adjacent pens.  There was no difference in total mortality; 
however, there was a difference in BVDV/enteritis mortality.1  In a small pen study, Elam et al 
found no differences in animal health within pens and adjacent pens that had short- or long-term 
exposure to PI-BVDV animals.5  In our current study, adjacent pens were not analyzed because 
there were no fence-line water tanks in the feedlot.  In addition, all groups were housed next to 
pens that did not contain a PI animal at any point during the study. 
Interestingly, there was a significant difference in the morbidity between cattle that had 
no exposure to a PI-BVDV animal (7.2% morbidity) and those that were exposed (2.3% 
morbidity rate; P = 0.01).  In a longitudinal study at a custom cattle feeding operation in Iowa, 
OConnor et al reported that inclusion of a calf PI with BVDV in a pen was associated with 
reduced disease risk for undifferentiated bovine respiratory tract disease (UBRTD) and chronic 
disease (odds ratio < 1).9  In that study, the authors reported a decrease of approximately 30% in 
the risk of UBRTD in a pen containing a PI-BVDV calf compared with the risk of UBRTD in a 
pen without a PI-BVDV calf.  Furthermore, the mean cumulative incidence of morbidity 
attributable to any disease during the feeding period was lowest in pens that contained cattle 
from a single source with a PI-BVDV calf, compared with the mean cumulative incidence of 
morbidity from pens containing cattle from a single source and no PI-BVDV calf.9  This suggests 
that exposure to a PI-BVDV calf at an early stage of development while experiencing minimal 
stress may actually better prepare herdmates of PI calves for disease exposure upon feedlot entry, 
compared to calves with no prior exposure to a PI animal. 
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In our current study we found no differences in the performance variables during the 
study period.  Carcass quality was not affected and no differences were found for the majority of 
yield grade data; however, there was an increase in yield grade 4 and 5 carcasses in the exposed 
group.  Results from the small pen study by Elam et al found no differences in final BW, DMI, 
ADG and G:F in calves with direct or adjacent exposure to a PI-BVDV calf, but they did find a 
tendency (P ≤ 0.12) for PI exposed cattle to gain less through day 28.  However, these 
differences were not noticeable by day 56.  In a large pen study,1 no significant differences in 
ADG or dry matter to gain ratio between PI pens and non-PI pens of cattle were found.  
A limitation to the present study design was the lack of a treatment group that included 
pens that contained a PI-BVDV animal that was not removed after identification.  This would 
have allowed for a greater understanding of the full impact that a calf PI with BVDV could have 
on health and performance measures under our experimental conditions.   Future research efforts 
should be directed towards understanding the role of a PI-BVDV animal when it is not removed 
from the pen within commercial feeding systems. 
CONCLUSIONS 
Under the conditions of this study, there were no harmful outcomes when newly arrived 
feeder cattle were exposed to a PI animal for one to two days following feedlot entry.   
 
Endnote   
aDectomax injectable, Pfizer Animal Health, New York, NY 
bArsenal 4.1, Novartis Animal Health, Greensboro, NC 
cComponent E-S, Vetlife, West Des Moines, IA 
dVista 5 SQ, Intervet, Millsboro, DE 
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eVision 7, Intervet, Millsoboro, DE 
fDraxxin, Pfizer Animal Health, New York, NY 
gNuflor, Schering Plough Animal Health, Union, NJ 
hExcenel, Pfizer Animal Health, New York, NY 
iIdexx Laboratories Inc., Westbrook, ME 
jWalco International, Amarillo, TX 
kSAS System for Windows 9.1.3, SAS Inst. Inc., Cary, NC 
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Table 3.1.  Health data from pens of feeder cattle that did (PI-pen) or did not (non-PI pen) have 
contact with a persistently infected (PI) calf on arrival to a commercial feedlot.   Variables are 
least squares means expressed as percents. 
 
Variable    PI pen  Non-PI pen      SEM        P-value 
No. pens           6          6     
No. animals        909         668 
Initial weight (lb)     647         679      50.9     0.66 
Initial BRD treatment (%)1     2.7          7.0       3.0        < 0.01 
Retreatment rate (%)2      4.8          0.5       3.4              0.29 
Mortality rate (%)3      1.6          1.2       0.5      0.41 
1Initial bovine respiratory disease (BRD) treatment rate is the number of animals treated for BRD 
divided by the number of animals placed in the study. 
2Retreatment rate is the number of cattle treated a second or third time for BRD divided by the 
number of animals first treated for BRD. 
3Mortality rate is the number of cattle that died of BRD divided by the number of animals placed 
in the study. 
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Table 3.2.  Performance data from pens of feeder cattle that did (PI pen) or did not (non-PI pen) 
have contact with a persistently infected (PI) calf on arrival to a commercial feedlot.   Variables 
presented are least squares means. 
 
Variable   PI Pen  Non-PI Pen             SEM              P-value 
Initial BW, lb      647           679   50.9     0.66 
Final BW, lb     1216          1147   36.9     0.22 
ADG, lb/day      2.6            2.4   0.16      0.28 
DMI, lb/day     20.1           19.3    1.3        0.67 
F:G        7.7             8.1   0.38       0.43 
COG, $/lb     0.86            0.87   0.06       0.92 
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Table 3.3.  Least squares means carcass characteristics from pens of feeder cattle that did (PI 
pen) or did not (non-PI pen) have contact with a persistently infected (PI) calf on arrival to a 
commercial feedlot. 
 
Variable   PI pen     Non-PI pen            SEM              P-value 
Dressing percent (%)     62.8             62.4  0.52     0.55 
USDA Quality Grade 
Choice/Prime (%)   81.7         81.4   6.1     0.46 
Select or Other (%)    18.3         18.8   6.1      0.46 
USDA Yield Grade 
1 and 2 (%)     26          31   4.4        0.46 
3 (%)      59.8          62   3.8       0.26 
4 and 5 (%)     14.2           7   3.2       0.01 
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CHAPTER 4 - The Survival of Bovine Viral Diarrhea Virus on 
Materials Associated with Livestock Production 
 
ABSTRACT 
Cattle that are persistently infected with bovine viral diarrhea virus (BVDV) serve as the 
predominant reservoir of virus for in-contact cattle.  Persistently infected cattle are processed and 
housed within facilities that are shared with naïve cattle.  Furthermore, the handlers of PI-BVDV 
cattle may have multiple interactions with naïve cattle and may exacerbate transmission of the 
virus.  To date, there are limited published reports of the survival of BVDV on materials 
commonly associated with livestock production.  Through the use of a controlled environment, 
we characterized the survival of a non-cytopathic, Type 1b BVDV isolate from a persistently 
infected animal on materials commonly associated with livestock production that may serve as 
fomites for the transmission of BVDV. 
 
INTRODUCTION 
Transmission of pathogens from infected to susceptible hosts occurs by direct or indirect 
means.  Indirect transmission may take place via water, food, air or contaminated fomites.  A 
critical factor in the indirect transmission of any pathogen is its ability to survive in the 
environment.  Excretion of large amounts of respiratory viruses in excretions or secretions of 
infected animals may lead to environmental contamination.  Viral survival for any length of time 
on environmental surfaces and fomites may help their transmission to susceptible hosts8. 
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Transmission of bovine viral diarrhea virus (BVDV) is thought to be through direct contact via 
oral and nasal routes; however, aersolization has also been reported 17.   
Cattle persistently infected with BVDV can shed BVDV into the environment through 
secretions and excretions, including nasal discharges, saliva, semen, urine, tears, and to a lesser 
extent, feces.  Work by Brock et al. focused on characterizing the viremia associated with PI-
BVDV calves.  From their published report, all persistently infected calves in the study were 
viremic by 42 days of age.  Further characterization of 7 mature PI-BVDV animals found a range 
of outcomes over time.  The majority of the animals, 5 of 7, declined in viremia by one 10-fold 
dilution over a two year period.  Of the two remaining animals in the study, one had a 10 fold 
increase in the level of viremia during the 2 year period, while the viremia of the other animal 
fell below detectable levels by serum virus isolation using cell culture1.   
The manifestations of BVDV are varied and are of economical concerns to producers at 
all levels of production as it plays a role in bovine respiratory tract disease and 
immunosuppression of stocker and feedlot cattle4.  At the cow-calf level, the outcome of BVDV 
fetal infections in susceptible heifers and cows is dependent on the age of the fetus when 
exposed.  Infection can result in abortion, stillbirths, congenital malformations and birth of 
persistently infected (PI) calves.  Persistent infection in a calf develops when a susceptible heifer 
or cow is exposed to a noncytopathic BVDV during pregnancy at approximately 45 to 125 days 
of gestation6.  The prevalence of persistently infected BVDV feeder cattle entering feedlots is 
estimated to be 0.3 %5.  PI cattle are important sources of virus for animals in direct or close 
contact.  In a recent study the risk of initial treatment for bovine respiratory disease (BRD) was 
43 % greater in cattle exposed to a PI calf5.  Of the various biotypes, genotypes and subtypes of 
BVDV, Type 1b was found to be the most prevalent type isolated from persistently infected 
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BVDV cattle entering a feedlot2.  Persistently infected calves tend to have lower growth rates 
and often die from classic mucosal disease or other diseases during the feeding period9.    
Survival of BVDV in the environment away from the host is important to its ability to 
spread.  In general, pestiviruses have very limited ability to maintain their infectivity outside the 
host.  BVDV rapidly loses infectivity after contact with organic solvents and pH outside the 
range of 6.7 to 9.313.  Its sensitivity to low pH increases as environmental temperatures increase 
from 4°C to 37°C13.  Both biotypes are equally sensitive to temperature and pH.  Other 
pestiviruses are readily inactivated by heat, desiccation, ultraviolet light, detergents, and organic 
solvents14.  Experimentally, it has been shown that BVDV can be spread by fomites.  
Specifically, rectal sleeves, intravenous needles, and nose tongs have been implicated15, 16.   
To date there are no published reports on the survival of bovine viral diarrhea virus on other 
important materials associated with livestock production.  Therefore, the objective of this study 
was to assess the survival of a non-cytopathic, Type 1b, BVDV on materials commonly used or 
encountered in livestock production. 
MATERIALS AND METHODS 
Virus 
The BVDV strain CA0401186a was used for testing survival on fomites.  The 
CA0401186 strain was obtained from Dr. Julia Ridpath (NADC, Ames, IA).  Strain 
CA0401186a was isolated from the tissues of a PI calf submitted to the National Animal Disease 
Center (NADC) by diagnosticians from the Tulare Laboratory of the California Animal Health 
and Food Safety Laboratory.  The calf was one of 24 premature calves with brain and skeletal 
deformities born to heifers in one herd.  It was one of seven calves from the outbreak that 
suffered from brachygnathism.  CA0401186 has been characterized as non-cytopathic based on 
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growth characteristics in Madin-Darby bovine kidney (MDBK) cells.  Based on comparison of 
sequences from the 5 UTR, CA0401186a has been segregated to the BVDV 1b subgenotype 
(Ridpath et al.).   
 
Preparation of Viral Suspensions 
Virus was propagated in bovine turbinate (BT) cells to produce a single lot of virus for 
the study.  After propagation of the single lot of virus, it was aliquoted, frozen, and stored at  
80°C for future use.  Two vials of virus, the first and last aliquot of the single lot, were used for 
determination of the titer.  After the titer was determined, 2 working concentrations of virus were 
made for application to fomites.  The first was a 2x 4.1 log 10 median tissue culture infective dose 
(TCID50)/ml, and the second was a 3x 4.1 log 10 TCID50/ml solutions.  Each respective working 
concentration of virus was diluted in either phosphate buffered saline (PBS; pH=7.4; Cellgro, 
Manassas, VA) or a 20 % mucus/PBS solution (pH = 7.4).   
 
Preparation of Mucus 
A synthetic mucus was prepared that contained 1 g guar gum, 0.5 g dried type II mucin 
from porcine stomach, 0.26 g monobasic potassium phosphate, 1.57 g dibasic potassium 
phosphate, 1 ml 0.1 M sodium borate solution, and 96.2 g distilled water10.  All chemicals were 
purchased from Sigma-Aldrich.  The mixing process involved slow dissolution of guar gum into 
90% of the distilled water using a standard magnetic stir bar.  After complete hydration, noted by 
a visual increase of the solutions viscosity, mucin was slowly added.  While the mucin mixed, 
the buffer salts were dissolved into the remaining 10% of the distilled water and then slowly 
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added to the viscous solution.  Once mixed well, the borate solution was added to the solution.  
The synthetic mucus was then sterilized by autoclaving. 
 
Preparation and Inoculation of Fomite Samples 
All fomites were replicated three times.  Virus was diluted in either 20 % mucus PBS or 
PBS and applied to the fomite.  For this trial temperature and humidity were monitored.  For the 
three independent trials, the range of the room temperature was 77  82°F and the range of 
relative humidity was 22  27 %.      
 
Paper (computer print paper), latex glove material, and clothing (a 100 % cotton t-shirt, denim 
jeans) 
One centimeter squares were cut from each of the materials.  They were sterilized by 
autoclaving, and after drying each piece was placed in a separate well of a 24 well culture plate 
purchased through (Greiner Bio-One North America, Monroe, NC).  A total of 40 µl, in two 
separate 20 µl aliquots, of a 2x 4.1 log 10 TCID50/ml virus suspension was added to each fomite.   
 
Wood (pine, not treated with preservative), rubber (Wellington boot), metal (galvanized vs. 
enameled),  
One centimeter squares were cut, autoclaved and allowed to dry.  Each fomite was placed 
in a separate well of a 6 well culture plate (Greiner Bio-One North America, Monroe, NC).  A 
total of 40 µl, in two separate 20 µl aliquots, of a 2x 4.1 log 10 TCID50/ml virus suspension was 
added to each fomite. 
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Mineral, Salt, and Molasses Urea Blocks 
An approximate 0.5  1.0 cubic centimeter piece of mineral, salt, or of a molasses urea 
lick were isolated from the main block or lick using a hammer and chisel.  A total of 40 µl, in 
two separate 20 µl aliquots, of a 2x 4.1 log 10 TCID50/ml virus suspension was added to each 
fomite. 
 
Total Mixed Ration and Pen floor soil/manure mix 
Aliquots of 0.3 g of each material were weighed, placed into a 2.0 ml centrifuge tube 
(Continental Lab Products, San Diego, CA), autoclaved, and allowed to dry prior to use.  A total 
of 40 µl, in one aliquot, of a 3x 4.1 log 10 TCID50/ml virus suspension was added to each fomite.  
 
Water & Phosphate Buffered Saline(PBS) 
Distilled water (Cellgro, Manassas, VA) and PBS (Cellgro, Manassas, VA) were 
autoclaved.  After autoclaving, 40 µl of a 2x 4.1 log 10 TCID50/ml virus suspension was added.   
 
Collection of Samples 
Samples were collected immediately after the virus suspension was applied to the fomite 
(0 hour).  Additionally, samples were collected at 1, 2, 4, 6, 8, 24, 48, and 96 hours.  Fomites 
were eluted with 1.0 ml (paper, latex, cotton t-shirt, denim, rubber, metal (galvanized and 
enameled), wood, mineral block, salt block, molasses urea lick) or 1.5 ml (feed and dirt) of virus 
maintenance media.  Virus maintenance media (VMM) contained 480 ml Minimum Essential 
Medium Eagle (MEM) supplemented with Earles Salts (Cellgro, Manassas, VA), 10 ml horse 
serum (Atlanta Biologicals, Lawrenceville, GA) 5 ml of a stock antibiotic/antimycotic (10,000 
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U/ml penicillin; 10,000 ug/ml streptomycin; 25 ug/ml amphotericin B; Atlanta Biologicals, 
Lawrenceville, GA), and 5 ml of a stock 200 mM L-glutamine (Atlanta Biologicals, 
Lawrenceville, GA). 
 
Virus Detection 
Virus isolation in BT cells was attempted on every sample.  The propagation and 
detection has been described previously (Saliki et al. 1997).  Briefly, BT cells were seeded two 
days prior to use into 96 well cell culture microtiter (Greiner Bio-One North America, Monroe, 
NC).  A total  of 100 µl of the eluted sample was added in triplicate to each respective well.  
After plating all fomite samples, 100 µl of virus maintenance media was added to all wells.  
After a four day incubation at 37°C in 5 % CO2, the plates were frozen at  80 °C and thawed for 
a total of three consecutive times.  After the last freeze-thaw, 100 µl of the supernatant for each 
respective sample and 100 µl of virus maintenance media were transferred to a two day old 96 
well cell culture microtiter plate previously seeded with BT cells.  This methodology was 
completed an additional two times, thus creating a three pass virus isolation.  After the third pass, 
the media was removed and the plates were dried at room temperature. After thoroughly drying, 
the monolayers were fixed in a 20 % acetone PBS solution for 10 minutes and then allowed to air 
dry.  The fixed monolayers were incubated with a 1:400 dilution of the BVDV monoclonal 
antibody 20.10.6 in PBS containing 0.05% Tween 20 (Sigma, St. Louis, MO) for 45 minutes at 
37°C.  Following four washes with PBS containing 0.05% Tween 20, the plates were incubated 
with a 1:400 dilution of biotinylated rabbit anti-mouse IgG (Invitrogen, Carlsbad, CA) in binding 
buffer supplemented with 60% chicken serum (Atlanta Biologicals, Lawrenceville, GA) for 45 
minutes at 37°C.  Following a wash step as above, a 1:1000 dilution of peroxidase-conjugated 
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streptavidin (Invitrogen, Carlsbad, CA) was added and the plate was incubated for 45 minutes at 
37°C.  After a final wash, substrate containing 280 µg of 3-amino-9-ethylcarbazole (Invitrogen, 
Carlsbad, CA) per ml and 0.01% hydrogen peroxide in 50 mM acetate buffer (pH 5.0) was added 
and the mixture was incubated at 37°C in the dark.  A positive reaction was recorded when there 
was an appearance of a red intracellular precipitate after 30 minutes.  Test samples were 
considered positive if they produced, in at least one well, distinct cytoplasmic staining.  If there 
was no color development, the sample was deemed negative. 
 
Data Analysis 
 
Data was analyzed using the logistic procedure in STATA 10.1 (College Station, TX).  
The data was transformed to model the effect of time on the likelihood of recovering virus at 
each time point using logistic regression.  In order to achieve model stability, all of the 96 hour 
time-point observations were dropped because of lack of variability in the data (predicted no 
virus present perfectly).  Also, observations for the fomites: cotton t-shirt, denim, total mixed 
ration mineral lick, salt lick, and molasses urea lick were dropped as they perfectly predicted that 
no virus was found.  Therefore, the logistic model was derived from a total of 486 observations.  
Due to the inherent study design, only the first order model was explored.  Therefore, no 
interactions were statistically analyzed.  After achieving a satisfactory model, the PRVALUE 
procedure in STATA (College Station, TX) was used to achieve model adjusted risk estimates 
and corresponding 95% confidence intervals for the risk of finding virus present at each time 
point for each fomite (metal, wood, rubber, etc) and treatment (PBS & mucus).  This data was 
then organized and graphically shown using error bars at each data point to give a visual 
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representation of the data and the relative significance of any differences between treatments at 
each time point.  
RESULTS 
 When controlling for treatment, there were visually discernable differences in survival of 
BVDV strain CA040118a between fomite (Figure 4.1).  The probability of virus being present 
decreased as time of incubation increased.  The aqueous solutions (water and PBS), most non-
porous materials (latex and enameled metal), and one porous material (paper) tended to have the 
highest probability of recovering virus.  One non-porous material (galvanized metal) and two 
porous materials (soil and pine) tended to have the lowest probability of recovering virus.   
 
Survival on paper 
 On paper, BVDV strain CA0401186a tended to have a higher risk of being isolated in 
mucus than PBS (Figure 4.2; P = 0.052).  The risk of virus being present decreased as time of 
incubation increased for both mucus viral suspension (MV) and PBS viral suspension (PV).  
Visually there was a significant difference between MV and PV at 2, 4, and 6 hours post 
incubation based on non-overlapping error bars.  The treatment*time interaction for this fomite 
was examined and found to not be significant (P = 0.076).  Characterization of survival revealed 
there was a 94 % chance that virus would be present at 1 hour for MV and a 62 % chance that 
virus would be present at 1 hour for PV.  At 6 hours post incubation, there was only a 39 % 
chance that virus would be present in MV group compared to 7 % in the PV group.  By 48 hours 
post incubation, there was less than a 7 % chance that virus would be present in either group.  
However, these differences between treatments were not statistically significant.  
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Survival on Latex 
On latex, BVDV strain CA0401186a generally survived longer in mucus than PBS 
(Figure 4.3; P = 0.075).  The risk of virus being present decreased as time of incubation 
increased for both MV and PV.  Visually there was a significant difference between MV and PV 
at 4 and 6 hours post incubation based on non-overlapping error bars.  The treatment*time 
interaction could not be determined due to co-linearity.  Characterization of survival revealed 
there was a 98 % chance that virus would be present at 1 hour for the MV and an 85 % chance 
that virus would be present at 1 hour for PV.  At 6 hours post incubation, there was a 70 % 
chance that virus would be present in MV group compared to 20 % in the PV group.  By 48 
hours post incubation, there was a 20 % chance that virus would be present in the MV group and 
less than 3 % in the PV group. With the exception of 6 hours post incubation, there was no 
difference in survival between treatments for 1 and 48 hours post incubation. 
 
Survival on Rubber 
On rubber from a wellington boot, BVDV strain CA0401186a generally survived longer 
in mucus than PBS (Figure 4.4; P = 0.638).  The risk of virus being present decreased as time of 
incubation increased for both MV and PV.  Visually there was a significant difference between 
MV and PV at 1, 2, and 4 hours post incubation based on non-overlapping error bars.  The 
treatment*time interaction for this fomite was found to be significant (P = 0.057) with the earlier 
time points of 1, 2, and 4 hours being different than the later time points.  Characterization of 
survival revealed there was an 89 % chance that virus would be present at 1 hour for MV and a 
46 % chance that virus would be present at 1 hour for PV.  At 6 hours post incubation, there was 
a 25 % chance that virus would be present in MV compared to 4 % in the PV.  By 48 hours post 
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incubation, there was less than a 4 % chance of survival from either group.  With the exception 
of 1 hour post incubation, there was no difference in survival between treatments for 6 and 48 
hours post incubation. 
 
Survival on Pine (not treated with preservative) 
The survival of BVDV strain CA0401186a was reduced when applied to pine that was 
not treated with preservatives (Figure 4.5).  The risk of virus being present decreased as time of 
incubation increased for both MV and PV.  There were no statistical differences between MV 
and PV based on non-overlapping error bars.  Characterization of survival revealed there was a 
31 % chance that virus would be present at 1 hour for MV and a 5 % chance that virus would be 
present at 1 hour for PV.  At 6 hours there was less than a 2 % chance that virus would be 
present for either group.  At 8 hours and beyond, there was minimal chance (< 1 %) of the virus 
being present. However, these differences between treatments were not statistically significant.  
 
Survival on Galvanized Metal 
The survival of BVDV strain CA0401186a was reduced when applied to galvanized 
metal (Figure 4.6).  The risk of virus being present decreased as time of incubation increased for 
both MV and PV.  Visually there was no significant difference between MV and PV based on 
non-overlapping error bars.  Characterization of survival revealed there was a 22 % chance that 
virus would be present at 1 hour for MV and  a 3 % chance that virus would be present at 1 hour 
for PV.  At 6 hours there was less than a 2 % chance that virus would be present for either group.  
At 8 hours and beyond, there was minimal chance (< 1%) of the virus being present.  However, 
these differences between treatments were not statistically significant.  
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Survival on Enameled Metal 
On enameled metal, BVDV strain CA0401186a generally survived longer in mucus than 
PBS (Figure 4.7; P < 0.05).  The risk of virus being present decreased as time of incubation 
increased for both MV and PV. Visually there was a significant difference between MV and PV 
at 1, 2, and 4 hours post incubation based on non-overlapping error bars.  The treatment*time 
interaction could not be determined due to co-linearity.  Unlike the lack of survival on 
galvanized metal, there was a 89 % chance that virus would be present at 1 hour for MV and a 46 
% chance that virus would be present at 1 hour for PV.  At 6 hours post incubation, there was a 
25 % chance that virus would be present in the MV group compared to 4 % in the PV group.  By 
48 hours post incubation, there was less than a 4 % chance of survival from either group. With 
the exception of 1 hour post incubation, there was no difference in survival between treatments 
for 6 and 48 hours post incubation. 
 
Survival in Soil 
The survival of BVDV strain CA0401186a was reduced when applied to soil (Figure 
4.8).  The risk of virus being present decreased as time of incubation increased for both MV and 
PV.  Visually there was no significant difference between MV and PV based on non-overlapping 
error bars.  A treatment*time interaction could not be determined as MV treatment predicted 
failure (no virus) for the majority of time points.  Characterization of survival revealed there was 
a 48 % chance that virus would be present at 1 hour for MV and roughly 9 % chance that virus 
would be present at 1 hour for PV.  At 6 hours there was less than 4 % chance that virus would 
be present for either group.  At 8 hours and beyond, there was minimal chance (< 1 %) of the 
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virus being present.  However, these differences between treatments were not statistically 
significant.  
 
Survival in Phosphate Buffered Saline 
When added to PBS, BVDV strain CA0401186a generally survived longer in mucus than 
PBS (Figure 4.9; P = 0.052).  The risk of virus being present decreased as time of incubation 
increased for both MV and PV.  The treatment*time interaction for PBS was not statistically 
significant (P = 0.12).  Visually there was a significant difference between MV and PV at 2 and 4 
hours post incubation based on non-overlapping error bars.  Characterization of survival revealed 
there was a 95 % chance that virus would be present at 1 hour for MV and a 66 % chance that 
virus would be present at 1 hour for PV.  At 6 hours post incubation, there was roughly a 43 % 
chance that virus would be present in the MV group compared to less than 8 % in the PV group.  
By 48 hours post incubation, there was less than an 8% chance of survival from either group. 
However, these differences between treatments were not statistically significant. 
 
Survival in Water 
When added to water, BVDV strain CA0401186a generally survived longer in mucus 
than PBS (Figure 4.10).  The risk of virus being present decreased as time of incubation 
increased for both MV and PV.  Visually there was a significant difference between MV and PV 
at 4 and 6 hours post incubation based on non-overlapping error bars.  Characterization of 
survival revealed there was a 98 % chance that virus would be present at 1 hour for MV and an 
82 % chance that virus would be present at 1 hour for PV.  At 6 hours post incubation, there was 
a 64 % chance that virus would be present in the MV group compared to 17 % in the PV group.  
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By 48 hours post incubation, there was a 16 % chance that virus would be present in MV group 
compared to 2 % in the PV group.  With the exception of 6 hours post incubation, there was no 
difference in survival between treatments for 1 and 48 hours post incubation. 
 
Other Fomites 
 Data for the cotton t-shirt, denim, total mixed ration, mineral lick, salt lick, and molasses 
urea lick were not included in the analysis.  No virus was recovered from the denim and cotton t-
shirt elutions.  For the total mixed ration, for one replicate, we recovered virus for up to 8 hours 
post application; however, all other replicates were negative.  For the molasses urea lick in all 
three replicates, there was contamination, which invalidated the analysis.  Lastly, the mineral and 
salt licks were negative at all time points.   
 
DISCUSSION 
In previous fomites trials, the experimental design focused on identifying a PI animal and 
then exposing the desired fomite (nose tongs, rectal sleeve, etc) to the PI animal and using the 
exposed fomite for exposure to the naïve animal15, 16.  Response variables in those trials 
consisted of clinical signs, virus isolation, and serum neutralization titers.  For this trial, in a 
laboratory setting, we applied the virus to the fomite and then eluted the fomite at desired time 
points to determine if virus could be recovered.  The objective was to determine the survival of a 
non-cytopathic, Type 1 BVDV on materials commonly used or encountered in livestock 
production.  We chose a non-cytopathic biotype of BVDV because it is the biotype that is 
associated with the development of PI BVDV cattle.   We chose to use the Type 1b genotype of 
BVDV because it was the genotype most often recovered from newly arrived cattle that were 
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found to be PI on arrival to a feedlot3.  In addition to selecting a ncp, Type 1b BVDV, the isolate 
we selected had a clinical history consistent with the ability to produce PI animals with 
developmental anomalies.  The concentration of the virus applied to the fomite was based on a 
previous publication18.  Grooms et al. used PI cows as a source of continual exposure of BVDV 
in a commercial fetal protection vaccine trial.  In that trial, BVDV was isolated from nasal swab 
specimens obtained from the PI cows.  Virus titer for each PI cow (n = 3) in the trial ranged from 
1.7 to 4.5 log10 CCID50.   
Two suspensions of virus were produced.   Virus was diluted in standard PBS or virus 
was diluted in a 20 % synthetic mucus PBS (pH 7.4).  The use of a synthetic mucus material in 
PBS was an attempt to achieve a reasonable system to test the survival of virus in a manner that 
is similar to natural exposure via nasal secretions.  The pH for the solutions was determined from 
unpublished data which measured the pH of bovine nasal mucus at the Great Plains Veterinary 
Education Center, Clay Center, NE (personal communication).  Prior to selecting the 20 % 
dilutional factor for the synthetic mucus, several dilutions were made (5, 10, 20, 50, 75, and 100 
%).  The 20 % dilutional factor was selected based on a subjective viscosity and consistency and 
an objective drying time.  For the 20 % dilution factor the consistency and viscosity was most 
similar to that of bovine nasal mucus.  The time from application of the MV to the fomite until 
the fomite was dry was approximately 30 minutes.  For isolation of the virus from the fomites, it 
was necessary to put the samples into an in vitro cell culture system.  Thus, the synthetic mucus 
was preferred over actual bovine mucus because of sterility.  For this trial temperature and 
humidity were monitored.  For the three independent trials, the range of the room temperature 
was 77  82°F and the range of relative humidity was 22  27 %.     
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Our method of virus detection was three (3) pass virus isolation assay.  We chose this 
method due to increased sensitivity.  In theory, the assay works by testing the initial sample, then 
after a defined time in cell culture, the cells and supernatants are frozen at - 80°C and thawed at 
room temperature, the freeze-thaw cycle continues two additional times.  After the last freeze 
thaw cycle, the supernatant is harvested and added to the culture media of newly plated cells and 
the entire process is completed two additional times until there has been three passes in cell 
culture.  Therefore, even one virion has the ability to multiply and be sufficient for detection.  A 
3-pass virus isolation assay not only allows us to detect virus, but it also allows for the detection 
of viable virus.  For polymerase chain reaction (PCR), the target for detecting the presence or 
absence of virus is deoxyribose nucleic acid (DNA).  Unfortunately, the mere presence of DNA 
does not allow for the detection of viable virus.  Conceivably, a real time-polymerase chain 
reaction (RT-PCR) would allow for quantification of virus and then an inference could possibly 
be made that replication may have occurred based on the number of viral transcripts. 
Data for the cotton t-shirt, denim, total mixed ration, mineral lick, salt lick, and molasses 
urea lick were not included in the analysis.  No virus was recovered from the denim and cotton t-
shirt elutions.  For the total mixed ration, for one replicate we recovered virus for up to 8 hours 
post application; however, all other replicates were negative.  For the molasses urea lick in all 
three replicates there was contamination, which invalidated the analysis.  Lastly, the mineral and 
salt licks were negative at all time points.  Interestingly, the tested cell monolayer was confluent 
and appeared healthy for the mineral and salt lick samples.  One possible reason for the negative 
results may be attributed to a change in the osmolality in the cell culture media.  Dialysis of the 
elutions prior to plating may have been beneficial to remove the salts from the elutions prior to 
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testing.  Another possible consideration would be testing the elutions by PCR to determine if an 
elution was positive for virus.  
 The absorbency of the materials may have some effect on the survival of BVDV.  On 
absorbent materials, virus suspensions dried very quickly and this may have influenced the 
survival on these materials.  When controlling for treatment, there was a discernable visual 
difference in the survival between non-absorbent materials (enameled metal, rubber boot, and 
latex glove) and absorbent materials (paper, cotton, soil, and pine).  Pine, which had one of the 
shortest survival times, was likely the most absorbent.   This may have had an effect on the 
sampling, making it more difficult to recover virus that had been absorbed.  The thickness of the 
pine may have hindered recovery of virus, since for paper, which had a higher chance of 
recovery, the elution volume was capable of penetrating the entire material and being recovered 
easily for testing.   
 The virus survived for the longest times when tested on latex and in PBS and water.  
Virus survived the longest when in mucus and when applied to water.  This is an interesting 
finding when considering livestock watering systems.  These systems can be used to provide 
drinking water to a number of cattle at any one time.  Thus, if a PI animal was present, and using 
a shared water source, it is conceivable that virus may persist and the water source would serve 
as a reservoir of virus for other cattle.  This scenario should also be assumed for acute BVDV 
infections as well.   
 One interesting finding was the result obtained from the galvanized metal.  The 
importance of this result is not clear.  The process of galvanization is a metallurgical process that 
is used to coat steel or iron with zinc.  The reason this is done is to prevent rust from occurring 
by taking advantage of the relative corrosion resistance of zinc.  The galvanized metal was 
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washed and autoclaved prior to use, so if the manufacturing process had introduced noxious 
chemicals they potentially would have been removed prior to our use.  Potentially, the 
application of zinc has an anti-viral or anti-viral survival effect. 
 Based on the findings of this study, the addition of a biosecurity plan for working with 
cattle is important and should be tailored accordingly.  The practice of washing boots, changing 
gloves, disinfecting livestock chutes and other equipment, and cleaning water tanks are important 
mechanisms that can mitigate the risk of virus transfer from fomites.      
 
 
CONCLUSIONS 
Under the conditions of this study, a ncp, Type 1b, BVDV was capable of surviving after 
application to various fomites.  When in the presence of mucus, BVDV was protected from 
degradation for longer periods of time then when not in the presence of mucus.   
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Figure 4.1.  Probability of virus being present at each time point post inoculation for each fomite 
controlling for treatment.  Each line represents the average of all six replicates (3 PBS and 3 
mucus) at each time point. 
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Figure 4.2.  Model adjusted risk estimates of virus being present on paper.  Based on three 
replicates at each time point for each treatment. 
 
 
 
 
 
 
 
 
 
 
 
Fomite Time (hr) Treatment Virus Present Lower 95% CI Upper 95% CI
Paper 1 PBS 62.06% 37.05% 87.06%
Paper 2 PBS 38.66% 14.00% 63.32%
Paper 4 PBS 19.57% 2.62% 36.53%
Paper 6 PBS 6.63% -0.78% 14.05%
Paper 8 PBS 3.05% -0.90% 6.99%
Paper 12 PBS 2.37% -0.85% 5.60%
Paper 24 PBS 1.24% -0.70% 3.19%
Paper 48 PBS 0.77% -0.60% 2.14%
Paper 1 Mucus 93.65% 86.70% 100.61%
Paper 2 Mucus 85.04% 71.04% 99.04%
Paper 4 Mucus 68.70% 45.82% 91.59%
Paper 6 Mucus 39.05% 12.89% 65.22%
Paper 8 Mucus 22.08% 1.27% 42.89%
Paper 12 Mucus 17.97% -0.66% 36.60%
Paper 24 Mucus 10.19% -3.16% 23.53%
Paper 48 Mucus 6.57% -3.66% 16.81%
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Figure 4.3.  Model adjusted risk estimates of virus being present on latex.  Based on three 
replicates at each time point for each treatment. 
Fomite Time (hr) Treatment Virus Present Lower 95% CI Upper 95% CI
latex 1 PBS 85.83% 72.51% 99.14%
latex 2 PBS 70.01% 48.00% 92.01%
latex 4 PBS 47.40% 21.19% 73.61%
latex 6 PBS 20.83% 2.13% 39.53%
latex 8 PBS 10.42% -1.18% 22.02%
latex 12 PBS 8.25% -1.53% 18.04%
latex 24 PBS 4.45% -1.82% 10.72%
latex 48 PBS 2.81% -1.76% 7.38%
latex 1 Mucus 98.20% 95.99% 100.42%
latex 2 Mucus 95.46% 90.41% 100.52%
latex 4 Mucus 89.05% 78.30% 99.70%
latex 6 Mucus 70.35% 47.54% 93.17%
latex 8 Mucus 51.20% 22.07% 80.34%
latex 12 Mucus 44.79% 14.89% 74.70%
latex 24 Mucus 29.58% 0.70% 58.46%
latex 48 Mucus 20.67% -5.44% 46.77%  
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Figure 4.4.  Model adjusted risk estimates of virus being present on rubber.  Based on three 
replicates at each time point for each treatment. 
 
 
 
 
 
 
 
 
 
 
Fomite Time (hr) Treatment Virus Present Lower 95% CI Upper 95% CI
Rubber 1 PBS 46.28% 19.54% 73.02%
Rubber 2 PBS 24.93% 4.86% 44.99%
Rubber 4 PBS 11.36% 0.04% 22.69%
Rubber 6 PBS 3.61% -0.79% 8.01%
Rubber 8 PBS 1.63% -0.63% 3.88%
Rubber 12 PBS 1.26% -0.56% 3.09%
Rubber 24 PBS 0.66% -0.42% 1.74%
Rubber 48 PBS 0.41% -0.34% 1.16%
Rubber 1 Mucus 88.60% 77.01% 100.18%
Rubber 2 Mucus 74.97% 54.44% 95.50%
Rubber 4 Mucus 53.63% 26.90% 80.35%
Rubber 6 Mucus 25.24% 3.78% 46.70%
Rubber 8 Mucus 12.99% -1.20% 27.18%
Rubber 12 Mucus 10.35% -1.80% 22.50%
Rubber 24 Mucus 5.64% -2.35% 13.63%
Rubber 48 Mucus 3.57% -2.30% 9.45%  
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Figure 4.5.  Model adjusted risk estimates of virus being present on pine.  Based on three  
replicates at each time point for each treatment. 
Fomite Time (hr) Treatment Virus Present Lower 95% CI Upper 95% CI
Pine 1 PBS 4.77% -2.05% 11.58%
Pine 2 PBS 1.89% -1.04% 4.83%
Pine 4 PBS 0.74% -0.49% 1.96%
Pine 6 PBS 0.22% -0.17% 0.61%
Pine 8 PBS 0.10% -0.09% 0.28%
Pine 12 PBS 0.07% -0.07% 0.22%
Pine 24 PBS 0.04% -0.04% 0.12%
Pine 48 PBS 0.02% -0.03% 0.08%
Pine 1 Mucus 31.12% 0.78% 61.46%
Pine 2 Mucus 14.83% -3.61% 33.26%
Pine 4 Mucus 6.30% -2.59% 15.19%
Pine 6 Mucus 1.92% -1.08% 4.92%
Pine 8 Mucus 0.86% -0.58% 2.30%
Pine 12 Mucus 0.67% -0.48% 1.81%
Pine 24 Mucus 0.35% -0.30% 0.99%
Pine 48 Mucus 0.22% -0.22% 0.65%  
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Figure 4.6.  Model adjusted risk estimates of virus being present on galvanized metal.  Based on 
three replicates at each time point for each treatment. 
Fomite Time (hr) Treatment Virus Present Lower 95% CI Upper 95% CI
Galvanized 1 PBS 2.95% -1.92% 7.81%
Galvanized 2 PBS 1.16% -0.88% 3.19%
Galvanized 4 PBS 0.45% -0.38% 1.28%
Galvanized 6 PBS 0.13% -0.13% 0.39%
Galvanized 8 PBS 0.06% -0.06% 0.18%
Galvanized 12 PBS 0.05% -0.05% 0.14%
Galvanized 24 PBS 0.02% -0.03% 0.08%
Galvanized 48 PBS 0.01% -0.02% 0.05%
Galvanized 1 Mucus 21.50% -5.79% 48.78%
Galvanized 2 Mucus 9.55% -4.84% 23.94%
Galvanized 4 Mucus 3.92% -2.51% 10.34%
Galvanized 6 Mucus 1.18% -0.90% 3.25%
Galvanized 8 Mucus 0.52% -0.45% 1.50%
Galvanized 12 Mucus 0.41% -0.36% 1.17%
Galvanized 24 Mucus 0.21% -0.22% 0.64%
Galvanized 48 Mucus 0.13% -0.16% 0.42%  
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Figure 4.7.  Model adjusted risk estimates of virus being present on enameled metal.  Based on 
three replicates at each time point for each treatment. 
Fomite Time (hr) Treatment Virus Present Lower 95% CI Upper 95% CI
Enameled 1 PBS 46.28% 19.54% 73.02%
Enameled 2 PBS 24.93% 4.86% 44.99%
Enameled 4 PBS 11.36% 0.04% 22.69%
Enameled 6 PBS 3.61% -0.79% 8.01%
Enameled 8 PBS 1.63% -0.63% 3.88%
Enameled 12 PBS 1.26% -0.56% 3.09%
Enameled 24 PBS 0.66% -0.42% 1.74%
Enameled 48 PBS 0.41% -0.34% 1.16%
Enameled 1 Mucus 88.60% 77.01% 100.18%
Enameled 2 Mucus 74.97% 54.44% 95.50%
Enameled 4 Mucus 53.63% 26.90% 80.35%
Enameled 6 Mucus 25.24% 3.78% 46.70%
Enameled 8 Mucus 12.99% -1.20% 27.18%
Enameled 12 Mucus 10.35% -1.80% 22.50%
Enameled 24 Mucus 5.64% -2.35% 13.63%
Enameled 48 Mucus 3.57% -2.30% 9.45%  
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Figure 4.8.  Model adjusted risk estimates of virus being present on soil.  Based on three 
replicates at each time point for each treatment. 
 
Fomite Time (hr) Treatment Virus Present Lower 95% CI Upper 95% CI
Soil 1 PBS 9.24% -1.80% 20.28%
Soil 2 PBS 3.78% -1.23% 8.79%
Soil 4 PBS 1.49% -0.68% 3.66%
Soil 6 PBS 0.44% -0.27% 1.15%
Soil 8 PBS 0.20% -0.14% 0.53%
Soil 12 PBS 0.15% -0.12% 0.42%
Soil 24 PBS 0.08% -0.07% 0.23%
Soil 48 PBS 0.05% -0.05% 0.15%
Soil 1 Mucus 47.88% 16.80% 78.97%
Soil 2 Mucus 26.15% 1.65% 50.64%
Soil 4 Mucus 12.03% -1.88% 25.94%
Soil 6 Mucus 3.84% -1.36% 9.03%
Soil 8 Mucus 1.73% -0.85% 4.31%
Soil 12 Mucus 1.35% -0.73% 3.42%
Soil 24 Mucus 0.70% -0.50% 1.90%
Soil 48 Mucus 0.44% -0.39% 1.26%  
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Figure 4.9. Model adjusted risk estimates of virus being present in PBS.  Based on three 
replicates at each time point for each treatment. 
Fomite Time (hr) Treatment Virus Present Lower 95% CI Upper 95% CI
PBS 1 PBS 65.57% 41.58% 89.55%
PBS 2 PBS 42.33% 17.04% 67.62%
PBS 4 PBS 22.08% 3.69% 40.48%
PBS 6 PBS 7.64% -0.72% 16.00%
PBS 8 PBS 3.53% -0.97% 8.03%
PBS 12 PBS 2.75% -0.94% 6.44%
PBS 24 PBS 1.44% -0.79% 3.68%
PBS 48 PBS 0.90% -0.68% 2.48%
PBS 1 Mucus 94.50% 88.38% 100.62%
PBS 2 Mucus 86.88% 74.28% 99.47%
PBS 4 Mucus 71.88% 50.36% 93.40%
PBS 6 Mucus 42.73% 15.97% 69.49%
PBS 8 Mucus 24.81% 2.41% 47.21%
PBS 12 Mucus 20.33% 0.02% 40.64%
PBS 24 Mucus 11.67% -3.27% 26.60%
PBS 48 Mucus 7.57% -4.03% 19.18%  
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Figure 4.10.  Model adjusted risk estimates of virus being present in water.  Based on three 
replicates at each time point for each treatment. 
 
Fomite Time (hr) Treatment Virus Present Lower 95% CI Upper 95% CI
Water 1 PBS 82.02% 66.06% 97.99%
Water 2 PBS 63.75% 39.74% 87.76%
Water 4 PBS 40.44% 15.16% 65.72%
Water 6 PBS 16.54% 0.80% 32.28%
Water 8 PBS 8.06% -1.25% 17.37%
Water 12 PBS 6.35% -1.43% 14.13%
Water 24 PBS 3.39% -1.51% 8.29%
Water 48 PBS 2.13% -1.41% 5.67%
Water 1 Mucus 97.63% 94.77% 100.48%
Water 2 Mucus 94.07% 87.67% 100.47%
Water 4 Mucus 85.96% 72.85% 99.08%
Water 6 Mucus 64.13% 39.13% 89.13%
Water 8 Mucus 44.15% 15.36% 72.94%
Water 12 Mucus 37.94% 9.34% 66.53%
Water 24 Mucus 24.04% -1.51% 49.60%
Water 48 Mucus 16.41% -5.65% 3.85%  
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CHAPTER 5 - Characterization of Testing and Longitudinal 
Prevalences for PI-BVDV Cattle in the Beef Industry 
 
ABSTRACT 
The objective of this study was to evaluate the sample submission forms from a 
commercial PI-BVDV testing laboratory located in central Kansas.  In all, 1,490 sample 
submission forms, representing 153,716 head of cattle, were partially or fully completed.  After 
reviewing the completed data set, we were able to analyze the PI-BVDV prevalence by weight, 
year, month, and by submitting client (cow-calf, stocker, or feedlot).  The overall PI-BVDV 
prevalence for all submitted samples was 0.34% (524/153,716).  Cattle with a weight of 300 lbs. 
or less had the highest prevalence (0.43%) and cattle with a weight of 701 lbs. or greater had the 
lowest prevalence (0.23%).  The model adjusted odds ratio (OR) of testing PI-BVDV positive for 
cattle weighing between 301 to ≤ 500 lbs., 501 to ≤ 700 lbs. or  ≥ 701 lbs. compared to cattle 
weighing ≤ 300 lbs. was  0.80 ( 95 % CI 0.58  1.06), 0.6 (95 % CI 0.45  0.80) and 0.73 (95% 
CI 0.56  0.96), respectively.   The highest yearly prevalence (Jan.  Dec.) occurred during 2007 
(0.37%).  The model adjusted ORs of cattle testing PI-BVDV in 2006 or 2008 compared to cattle 
being tested in 2007 were 0.99 (95 % CI 0.82  1.20) and 0.73 (95 % CI 0.54  0.99), 
respectively.  The peak number of head tested in a month occurred during October.  For the PI-
BVDV prevalence by month, January had the highest prevalence (0.44%), and the month of 
October had the lowest prevalence (0.21%).  Based on model adjusted ORs of cattle testing PI-
BVDV in October compared to cattle being tested in any other month, the months that were 
suggested to have an increase in the point estimate for the risk of indentifying PI-BVDV animals 
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were  January (OR = 2.63; 95 % CI 1.74  3.98), February (OR = 2.38; 95 % CI 1.61  3.53), 
March (OR = 1.9; 95 % CI 1.29  2.78), May (OR = 2.53; 95 % CI 1.65  3.89), September (OR 
= 2.06; 95 % CI 1.33  3.2), November (OR = 2.06; 95 % CI 1.46  2.90), and December (OR = 
2.06; 95 % CI 1.34  2.8).  When the submitting client was identified as primarily involved in the 
cow-calf, stocker, or feedlot industry, the overall prevalence by operation was 0.38%, 0.55%, 
and 0.31%, respectively.  The model adjusted OR of testing PI-BVDV for cow-calf or stocker 
cattle compared to feedlot cattle was 1.32 (95 % CI 0.93  1.88) and 2.10 (95 % CI 1.65  2.69), 
respectively.   
 
INTRODUCTION 
Bovine viral diarrhea virus (BVDV) is an important pathogen of cattle and can have a 
diversity of clinical outcomes that are largely dependent on the host and the infecting BVDV 
strain.   A detrimental clinical outcome is the manifestation of an in utero infection between 30 
and 125 days of gestation with a non-cytopathic biotype of BVDV.  If a fetus survives the 
infection, it can cause a persistently infected BVDV individual (Baker, 1985).   The significance 
of the PI-BVDV individual is the continual shedding of BVDV into the environment (Bolin et al. 
1987), which can allow for the propagation of the virus through not only acute infections, but 
also through the establishment of additional persistently infected individuals.  The risk of initial 
treatment for bovine respiratory disease (BRD) was 43 % greater in cattle exposed to a PI calf 
(Loneragan et al, 2003).  Persistently infected calves tend to have lower growth rates and often 
die from classic mucosal disease or other diseases during the feeding period (Taylor et al, 1997).   
To date, several research groups have evaluated the point prevalence of PI-BVDV 
individuals.  With respect to beef cattle, the prevalence of PI-BVDV animals entering 
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conventional feeding systems has ranged from 0.17 - 0.4 % (Loneragan et al, 2003, Larson et al, 
2005, Stevens et al, 2007, OConnor et al, 2005).  Furthermore, a recent study in Iowa evaluated 
the prevalence of PI-BVDV animals in spring born beef calves (n = 12,030) using antigen 
capture ELISA (ACE) and immunohistochemistry (IHC) to detect positive animals (OConnor et 
al, 2008).  In that study, calves were first tested by ACE (prevalence = 0.20%) and later tested by 
IHC (prevalence =  0.09%).  Furthermore, the herd level prevalence (n = 102), with at least one 
positive PI-BVDV calf, was reported to be 10.8 % by ACE and 3.9 % by IHC (OConnor et al, 
2008).  Interestingly, at the herd level, in a 5 state US based study, 3 % of randomly selected cow 
herds contained PI cattle (Wittum et al, 2001). 
Montana State Universitys Beef Quality Assurance program, in association with the 
Montana Stockgrowers Association, has developed the Montana BVD-PI Herd Biosecurity 
Project.  The aims of the project are to reduce disease potential in individual cow herds, add 
value to commercial and seedstock cattle, and be a template for on-ranch biosecurity.  The 
program seeks to screen the whole herd before breeding to avoid exposing pregnant cows to the 
BVDV during early gestation and establish surveillance by screening aborted fetuses, stillborns 
and pre-weaning deaths.  Initial screening is performed using pooled reverse transcriptase 
polymerase chain reaction (RT-PCR).  If the RT-PCR is positive, then 3 to 4 weeks post initial 
testing ear notch samples are collected from all suspect animals for confirmatory testing by 
immunohistochemistry (IHC).  In 2007, 408 herds were screened and 31 herds contained at least 
1 PI animal (7.8%).  The 408 herds represented approximately 106,600 head and there were 110 
confirmed PI animals (0.13 % or 1.03 PIs/1000 head). 
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In 2002, the Academy of Veterinary Consultants (AVC) presented a position statement 
on BVDV for eventual eradication of the virus in North America (Grotelueschen, 2002).   The 
BVDV position statement reads: 
 
The beef and dairy industries suffer enormous loss due to the effects of bovine viral 
diarrhea virus (BVDV) infection.  The highly mutable nature of the BVDV and the 
emergence of highly virulent strains of BVDV contribute to limited success of present 
control programs.  Also persistently infected cattle are the primary source of infection 
and effective testing procedures are available to identify those infected carriers.  
Therefore, it is the resolve of the Academy of Veterinary Consultants the beef and dairy 
industries adopt measures to control and target eventual eradication of BVDV from North 
America. 
Academy of Veterinary Consultants  November, 2001 
 
The AVCs position statement was endorsed in September of 2002 by the American Association 
of Bovine Practitioners Board of Directors and endorsed again in February of 2003 by the 
National Cattlemans Beef Associations Animal Health and Well Being Committee. 
 If BVDV is to be eradicated, it must first be controlled.  To control BVDV, transmission 
must be prevented, the agent must be eliminated, and immunity must be increased.  Biosecurity 
and biocontainment are important considerations for establishing control and the subsequent 
maintenance of eradication.  The fundamental components of BVDV control plan are: 1) prevent 
BVDV entry into herds; 2) vaccination in the event exposure occurs; 3) indentify BVDV infected 
herds and eliminate PI animals; and 4) monitor and document success (Smith et al, 2004).  
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Current issues that are being addressed to support eradication efforts are the development of 
simplified biosecurity and biocontainment formats, development of herd and individual animal 
level categories, and validate and determine the most appropriate use(s) of current and future 
tests for diagnosis of PI-BVDV status (Maas, 2007).   
 With respect to the need for validation and determination of the most appropriate use(s) 
of current and future tests for the diagnosis of PI-BVDV status, there are several methods for 
detecting PI-BVDV individuals: immunohistochemistry (IHC) on ear notch biopsies, microplate 
virus isolation, antigen capture enzyme linked immunosorbent assay (ACE) for serum and fresh 
tissue, polymerase chain reaction (PCR), and virus isolation.  Although there are a number of 
tests available to practitioners and producers, the BVDV antigen capture enzyme linked 
immunosorbent assay (ACE) is often used for the initial screening of feedlot cattle.  A number of 
sample handling practices have been evaluated and found to have little impact on test sensitivity 
and specificity of ACE testing for BVDV (Funk et al, 2008; Reed et al, 2008).  Recently, several 
tests for BVDV were applied to samples collected monthly for an 11 month period from 12 PI 
BVDV animals (Fulton et al, 2009).   The test population was comprised of the genotypes and 
subgenotypes of BVDV 1a, 1b, and 2a.  In that study, the antigen capture ELISA (ACE) and IHC 
tests on ear notches had acceptable levels of agreements between the two tests throughout the 
study period.   Therefore, with regards to our ability to accurately identify PI-BVDV animals as 
the first step in an eradication program, the use of ACE testing may be a useful tool for the 
identification and the removal of PI-BVDV animals.   
  To date, there have been no longitudinal studies to evaluate the prevalence of PI-BVDV 
individuals.  Therefore, the objectives of this study were to characterize the PI-BVDV 
prevalence by weight, month, year, and by submitting client (cow-calf, stocker, or feedlot).     
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MATERIALS AND METHODS 
Sample Population 
 A standardized form was used for gathering data for ear notch biopsy samples being 
submitted for ACE testing at a commercial testing facility.  Data was obtained from sample 
submission forms from January 2006 until April 2008.  Data obtained consisted of yard, date, 
pen, lot, tag numbers, total number of vials, tag color, average weight, order buyer, and state of 
origin.  Additionally, for further characterization of the test animal(s), the client was asked to 
identify the origin of the cattle as sale barn origin, started, yearling, Mexican, and/or natural.   
The owner of the testing facility, who was also the consulting veterinarian, identified each client 
who submitted samples for testing as a cow-calf, stocker, or feedlot operator. 
 
Antigen Capture ELISA 
Detection of BVDV antigen in skin specimens (ear notch) was performed using a 
commercial ACE kit.i  Results were calculated by the following equation: standardized optical 
density (OD) = (raw OD of sample  raw OD of negative control)/(raw OD of positive control  
raw OD of negative control).  Samples with standardized OD values < 0.20 were considered 
negative, and those with OD values > 0.39 were considered positive.  Samples with values from 
0.2 to 0.39 were retested with detector reagents with or without antibody.  Upon secondary 
analysis, no animals had values from 0.20  0.39.   
 
Data Analysis and Model Building 
Data were then imported from the spreadsheets into Stata 10 (Statacorp; College Station, 
TX) and reformatted as necessary.  The data were reported on the aggregate level such that the 
83 
 
authors only knew the number tested and the number positive for each lot of cattle.  The data 
were then expanded using lot as the cluster identifier to create a dataset that contained an 
individual observation for each animal tested.  Several new potential predictor variables were 
created from the data to be used in the model building process.  Weight was transformed into a 
four category variable ( ≤ 300 lbs., 301 - 500 lbs., 501 - 700 lbs.,  ≥700 lbs.) to better 
communicate perceived risks in these weights of cattle.  Variables were then analyzed for an 
association with a positive BVDV-PI test result using a Pearsons chi-square test.  Those with an 
association were entered as fixed effects into the predictive and descriptive models. 
The predictive and descriptive models were built using manual techniques using forward 
selection.  All variables associated (P < 0.05) with the outcome of interest in the univariable 
analysis were included in the main effects models.  All variables and their interactions were 
assessed using likelihood ratio tests or Wald-type tests where appropriate.  For the predictive 
model, only variables that were found to be statistically significant (P < 0.05) were retained in 
the model.  For the descriptive model, all variables of interest were retained in the model 
regardless of significance.  All referent variable categories, with the exception of weight 
category, were manually set to the category in which the largest number of observations occurred 
in order to make the model more robust.  
As variables were added to the model all variables were examined for evidence of 
confounding.  A confounder was defined as any non-intervening variable that resulted in a 20% 
or greater change in the coefficient of a significant variable when added to the model (Dohoo et 
al, 2003).  If two variables were identified as confounders, only one variable was retained in the 
model. 
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RESULTS 
In all, 1,490 sample submission forms, representing 153,716 head of cattle, were partially 
or fully completed.  Five hundred and twenty four (524) head of the 153,716 head tested positive 
by ACE testing, which was an overall prevalence of 0.34 %.  The mean number of head tested 
per sample submission form was 112 with a median of 91.  For submission forms that included 
the weight of the animals and the date of testing, 379 of the 118,084 animals tested positive by 
ACE for BVDV, which was an overall prevalence of 0.32 % (Table 5.1and Figure 5.1).  
Longitudinally, the range of the average weight of cattle that tested positive was 344  695 lbs 
(Figure 5.2).  Interestingly, the longitudinal range of the average weight of cattle that tested 
negative was 345  744 lbs (Figure 5.2).   Further characterization of weight revealed that calves 
with a weight of 300 lbs. or less had the highest prevalence (0.43 %; Figure 5.3), whereas calves 
with a weight of 701 lbs. or greater had the lowest prevalence (0.23 %; Figure 5.3).   
For the predictive model, all factors examined were not significant in the prediction of 
having a positive PI-BVDV animal.  Therefore, a descriptive model was developed to 
demonstrate the differences in factors of interest.  The final model included weight, year, month, 
and submitting client categorical variables.  The model adjusted odds ratio (OR) of testing PI-
BVDV positive for cattle weighing between 301 to ≤ 500 lbs. compared to cattle weighing ≤ 300 
lbs. was  0.80 ( 95 % CI, 0.58  1.06), which suggested a point estimate of a 20 % decrease in the 
risk of identifying PI-BVDV positive cattle weighing between 301 to ≤  500 lbs (Table 5.2).  
Additionally, the model adjusted ORs of testing PI-BVDV positive of cattle weighing between 
501 to ≤ 700 lbs or x ≥ 701 compared to cattle weighing  ≤ 300 lbs were 0.6 (95 % CI 0.45  
0.80) and 0.73 (95% CI 0.56  0.96), respectively, which suggested a point estimate of a 40 % 
and 27 % decrease in the risk of identifying PI-BVDV positive cattle, respectively.   
85 
 
We also characterized the prevalence of PI-BVDV prevalence by year of testing.  Of the 
three years that data was collected, the highest yearly prevalence occurred during 2007 (0.37 %; 
Table 5.3 and Figure 5.1).  The model adjusted ORs of cattle testing PI-BVDV in 2006 or 2008 
compared to cattle being tested in 2007 was 0.99 (95 % CI 0.82  1.20) and 0.73 (95 % CI 0.54  
0.99), respectively (Table 5.4).  In both 2006 and 2007, the peak number of head tested in a 
month occurred during October (Table 5.5; Figure 5.4).  The month of January had the highest 
prevalence (0.44 %; Table 5.5; Figure 5.5), while the month of October had the lowest 
prevalence (0.21 %; Table 5.5).  The model adjusted ORs of cattle testing PI-BVDV in October 
compared to cattle being tested in other months and being PI-BVDV positive, were completed 
and the data is summarized in Table 5.6.  The model adjusted ORs for January (OR = 2.63; 95 % 
CI 1.74  3.98), February (OR = 2.38; 95 % CI 1.61  3.53), March (OR = 1.9; 95 % CI 1.29  
2.78), May (OR = 2.53; 95 % CI 1.65  3.89), September (OR = 2.06; 95 % CI 1.33  3.2), 
November (OR = 2.06; 95 % CI 1.46  2.90), and December (OR = 2.06; 95 % CI 1.34  2.8) 
suggested these months have an increase in the point estimate compared to October for the risk 
of indentifying PI- BVDV animals. 
 We characterized the prevalence by the submitting client.  There were three main 
categories for submitting clients: cow-calf, stocker, or feedlot.  For clients that were identified as 
primarily involved in the cow-calf industry, there were 209 lots, which represented 11,116 head 
(Table 5.6).  There were 16 lots that contained at least 1 PI animal (7.6 %; 16/209).  There were a 
total of 42 positive animals, which represented an overall prevalence of 0.38%.  The average and 
median for the cattle that were tested per submission were 53 and 33, respectively.   The peak 
prevalence of PI animals occurred in November 2006 (2.7 %; Figure 5.6).  During November 
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2006, 769 head were tested and 21 PI animals were identified.  The peak number of animals 
tested occurred in October 2006 (n = 1088).   
For clients that were identified as primarily involved in the stocker industry, there were 
198 lots, which represented 16,086 head (Table 5.6).  There were 43 lots that contained at least 1 
PI-BVDV animal (21.7 %; 43/198).  There were a total of 89 positive animals, which represented 
an overall prevalence of 0.55%.  The average and median for the cattle that were tested per 
submission were 81 and 79, respectively.  The peak prevalence of PI animals occurred in January 
2008 (4.0%; Figure 5.7).   During January 2008, 4 lots of cattle were tested, which represented a 
total of 174 head.  Seven of the 174 head tested in January 2008 were positive by ACE.  
Interestingly, during January 2008, one of the lots tested contained 9 head that were purchased 
from a sale barn and contained 4 calves that were PI-BVDV. The peak number of head tested 
occurred in October 2006 (n = 3,198).  
For clients that were identified as primarily involved in the feedlot industry, there were 
1,067 lots, which represented 125,542 head (Table 5.6).  There were 246 lots that contained at 
least 1 PI-BVDV animal (23.1%; 246/1,067).  Additionally, there were 391 positive animals, 
which represented an overall prevalence of 0.31%.  The average and median for the cattle that 
were tested per submission were 117 and 92, respectively.   The peak prevalence of PI animals 
occurred in May 2007 (0.8%; Figure 5.8).   During May 2007, 2,249 head were tested and 18 
tested positive by ACE.   The number of head tested peaked during October of 2006 (n = 
11,728).  The model adjusted OR of testing PI-BVDV for cow-calf or stocker cattle compared to 
feedlot cattle was 1.32 (95 % CI 0.93  1.88) and 2.10 (95 % CI 1.65  2.69), respectively (Table 
5.7).   
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DISCUSSION 
The objective of this study was to evaluate the sample submission forms from a 
commercial BVDV testing laboratory located in central Kansas.  Sample submission forms were 
collected that represented a continuous 29 month testing period (Jan. 2006  Apr. 2008).  The 
sample submission form that clients were asked to complete at the time of specimen submission 
include an area for the client to provide information about the sample population.  Specifically, 
feedlot (if applicable), date, pen number, lot numbers, tag numbers, total number of vials, tag 
color, average weight, order buyer, and state of origin.  In all, 1,490 submission forms were used 
to complete the data set.  The majority of sample submission forms were only partially 
completed.  After reviewing the completed data set, we were able to analyze the prevalence by 
weight, month, year, and by submitting client (cow-calf, stocker, or feedlot). 
The overall prevalence of 0.34 % is consistent with other published studies (Loneragan et 
al, 2003, Larson et al, 2005, Stevens et al, 2007, OConnor et al, 2005).  The overall prevalences 
for 2006, 2007, and 2008 were 0.32 %, 0.37%, and 0.31 %, respectively. The ORs of cattle being 
tested in 2007 and PI-BVDV positive, compared to cattle being tested in 2006 or 2008 and PI-
BVDV positive, was 0.99 (95 % CI 0.82  1.20) and 0.73 (95 % CI 0.54  0.99), respectively.   
The OR for 2006 suggested that the likelihood of identifying PI-BVDV cattle in 2006 (P = 0.94) 
was not different than in 2007.  However, the OR for 2008 suggested a point estimate decrease 
of 27 % in identifying PI-BVDV cattle in 2008 (P = 0.046).  The exact reason for the decrease in 
2008 is not known, but may be attributable to only having the first 5 months of data from 2008, 
cattle arriving from different sources, increased number of vaccinated cattle or other reasons 
related to increased industry awareness of PI-BVDV contributing factors. 
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We were able to characterize the frequency of testing by month and prevalence by month.  
Regardless of year or operation, the peak number of head tested in any month occurred during 
October.  The increased number of head tested was most likely associated with the seasonal 
placement of cattle into the feedlot and subsequent testing of spring born calves.  The month of 
May had the highest prevalence.  The exact reason for this is not known; however, in months 
when fewer cattle were tested, the prevalence was increased.  One reason for the increased 
prevalence, while the number of head tested was decreased, could be that the tested animals met 
the criteria for diagnostic testing because of health status, case definition, or biosecurity 
concerns.  The model adjusted ORs of testing PI-BVDV positive for cattle being tested in 
October compared to cattle being tested in any other month suggested that there was an increase 
in the point estimate for the risk of identifying PI-BVDV animals in January, February, March, 
May, September, November, and December.   
Characterization of prevalence by weight was evaluated.  Cattle were categorized into 
one of four weight classes: x ≤ 300, 301 ≤ 500, 501 ≤ 700, or x ≥ 701.  The corresponding 
prevalences were 0.43 %, 0.37 %, 0.27 %, and 0.23 %, respectively.  The model adjusted odds 
ratio of testing BVDV-PI positive for cattle weighing between 301 to ≤ 500 lbs. compared to 
cattle weighing ≤ 300 lbs. was 0.80 ( 95 % CI, 0.58  1.06). This suggests a point estimate of a 
20 % decrease in the risk of identifying PI-BVDV positive cattle weighing between 301 to ≤ 500 
lbs.  Additionally, the ORs of cattle weighing between 501 to ≤ 700 lbs or  ≥ 701 compared to 
cattle weighing ≤ 300 lbs were 0.6 (95 % CI 0.45  0.80) and 0.73 (95% CI 0.56  0.96), 
respectively, which suggested a point estimate of a 40 % and 27 % decrease in the risk of 
identifying PI-BVDV positive cattle, respectively.  Therefore, the lightest weight cattle, x ≤ 300, 
were at highest risk for identifying positive animals in this dataset.   
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We were able to categorize the submitting client as either being primarily involved in 
cow-calf, stocker, or feedlot operations.  For clients that were identified as primarily involved in 
the cow-calf, stocker, or feedlot industry, the overall prevalence by operation was 0.38%, 0.55%, 
and 0.31%, respectively.   Further characterization of cow-calf operators revealed that 88 
operators had submitted samples.  Of the 88 operators, 7 had at least 1 PI-BVDV positive 
animals (7.9 %; 7/88).  This finding is strikingly similar to that of the Montana BVD-PI Herd 
Biosecurity Project in 2007, where 408 herds were screened and 31 herds contained at least 1 PI 
animal (7.8%).  The 408 herds represented approximately 106,600 head and 110 PI animals were 
positive (0.13 % or 1.03 PIs/1000 head).  Although at the herd level, our results were similar, 
there was a divergence when the total number of head tested was evaluated.  In our analysis, the 
88 herds represented 11,116 head and 42 PI animals were positive (0.38 % or 3.8 PIs/1000 head).  
The exact reason for the increased prevalence in the central KS herds is not known.  However, 
the difference for the individual animal prevalence may be attributable to the willingness of 
progressive Montana cow-calf producers to participate in a program associated with a beef 
quality assurance program.  The willingness to participate in such a program might infer a 
progressive management style with the expectation that few calves would be identified as PI.  
Whereas in the central KS herds, the willingness to participate was not mandated, nor subsidized, 
and may have been for personal gain to assist in marketing, maintenance or implementation of 
biosecurity, or meeting the criteria of a case definition which demonstrated a need for herd 
testing.   
For operators that were identified as being involved in the stocker industry, the 
prevalence was the highest of the three potential operations (0.55 %; 88/16,085).  The reason for 
the increased prevalence is most likely associated with increased concentration of cattle from 
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potentially diverse health backgrounds.  Given that the average cow herd in the United States is 
approximately 30 head, and the average number of head tested by stocker operators was 79, it 
seems likely that previous management is an important consideration for the increased 
prevalence.  Additionally, the act of purchasing calves with diverse health backgrounds may 
have prompted increased testing, and through increased testing the prevalence may be the true 
prevalence rather than a prevalence derived from more strategic and volunteered samples.  
Interestingly, the prevalence for feedlot operators was 0.31%.  This is an impressive reduction 
from the stocker prevalence of 0.55% that may be attributed to increase culling of BVDV-PI 
animals from backgrounding or stocker phases of the production system or an increased death 
rate.  It has been reported that PI-BVDV calves are often susceptible to mucosal disease.  
Mucosal disease, which typically is assumed to be 100% fatal, occurs when a cytopathic BVDV 
with a similar antigenic structure to the non-cytopathic strain that created the PI-BVDV calf 
avoids immune recognition.  By avoiding the immune system, the virus ravages the calf, which 
culminates in death.  If the true prevalence is 0.55% for stocker operations, it would be important 
to characterize mortality of stocker calves to determine if there was an increase in mortality 
associated with PI-BVDV animals.    
Lastly, the model adjusted odds ratio (OR) of testing BVDV-PI positive of cow-calf or 
stocker cattle compared to feedlot cattle, was 1.32 (95 % CI 0.93  1.88) and 2.10 (95 % CI 1.65 
 2.69), respectively.  The OR for cow-calf suggests there is a tendency for a point estimate 
increase of 32 % in identifying PI-BVDV cattle in cow-calf operations (P = 0.11).  The OR for 
stocker suggests that there is a point estimate increase of 210 % in identifying PI-BVDV in 
stocker operations.  This data taken together strongly implies that if BVDV is to be eradicated, 
testing and removal programs must be initiated at the level of the cow-calf producer.  In our 
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current study, there were more feedlot animals tested than animals from  cow-calf operations.  
Even more importantly, we test animals at the terminal point of the industry, when there is 
sufficient evidence to support that PI-BVDV individuals have little, if any, effect on the 
performance, health, and carcass characteristics of feedlot pen mates (Booker et al, 2008, Elam et 
al, 2008, Stevens et al, 2007 and 2009).  However, there is at least one published report showing 
a negative impact of PI-BVDV animals in a starter feedlot (Hessman et al, 2009).  The authors in 
that study found that exposure of the general population of feedlot cattle to PI-BVDV animals 
resulted in substantial costs attributable to negative effects on performance and increased 
fatalities.  The reason why marketing of PI-BVDV testing is so effective at the feedlot level, with 
the exception of the time of birth and at branding, is because it is a time in the production system 
that allows for easy sampling and compliance for removal of positive animals.    
How can we be successful in eradication of PI-BVDV at the cow-calf level?  It seems 
unlikely that we can pick a month for testing that would give an edge over any other month.  The 
best time for sampling would be at birth and removal of positive animals as soon as possible.  By 
testing at birth and removing soon thereafter, potentially the cycle of transmission for the herd 
would be broken.  However, the veterinarians, beef extension coordinators, and other pivotal 
industry leaders need to champion the cause for testing.  If we test and remove positive 
individuals, institute appropriate vaccination programs, and implement biosecurity plans, we will 
have a firm foundation for eradication.  There is one other very important concern for success 
based on a study conducted by OConnor et al (2007).   While trying to determine the prevalence 
of PI-BVDV beef cow-calf herds through a voluntary screening project, one very important 
pitfall was identified.  Specifically, of the 131 recruited producers, only 102 actually submitted 
samples, nearly a quarter dropped out because of an inconvenience to collect ear notch samples.  
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Furthermore, many of the producers in the study did not submit the samples as requested.  The 
authors requested that each producer ship his or her samples in coolers with ice packs; however, 
more often than not, many samples arrived in boxes with no insulation or cold packs.  Also, to 
save money on shipping many producers stored samples until calving was complete.  Based on 
this, it seems that if testing is to be initiated, it would be best to test and remove prior to breeding 
to break the transmission cycle. 
An eradication program for BVDV is possible, but the logistics for success need to be 
carefully evaluated, not only for compliance at the level of testing, but to ensure proper specimen 
management.  Additionally, veterinarians, beef extension coordinators, and other key opinion 
leaders need to be involved to initiate, maintain, and complete the project.  An ideal eradication 
program would be initiated at the cow-calf level with testing prior to breeding and utilize the 
ACE for determining test  positive and negative animals.   
 
CONCLUSIONS 
Cattle that weighed less than 300 lbs. had a greater likelihood of being PI-positive than 
cattle with increased weights.  Several months of the year had a greater likelihood of having PI-
positive animals.  Based on operation, cow-calf and stocker operations had a greater likelihood 
of having PI-positive animals as compared to feedlots.   
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Table 5.1.  The weight class tested and the number of lots, calves, and PI-BVDV positive 
calves with corresponding prevalence.  
Weight (lbs.) # of Lots # of Calves # of PI  Positive Raw Prevalence % 
≤ 300 149 20,640 89 0.43 
301 ≤ 500 240 29,971 112 0.37 
501 ≤ 700 502 52,476 144 0.27 
≥ 701 166 14,997 34 0.23 
Total 1,057 118,084 379 0.32 
 
 
 
Table 5.2   Association between weight and PI-BVDV prevalence. 
 
Weight of Tested Cattle (lbs.) OR 95 % CI P value 
x ≤ 300 1.00 NA NA 
301 ≤ 500 0.80 0.60  1.07 0.128 
501 ≤ 700 0.60 0.46  0.80 0.000 
701 ≤  x 0.73 0.56  0.96 0.023 
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Table 5.3   Characterization of PI-BVDV Prevalence by year of testing. 
 
Year # of Lots # of Calves # of PI  Positive Raw Prevalence % 
2006 654 66,174 215 0.32 
2007 599 64,833 240 0.37 
2008 227 22,709 67 0.31 
Total 1,480 152,632 522 0.34 
 
 
 
Table 5.4.  Association between year and PI-BVDV prevalence. 
 
Year Tested OR 95 % CI P value 
2006 0.99 0.82  1.20 0.94 
2007 1.00 NA NA 
2008 0.73 0.54  0.99 0.046 
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Table 5.5.   Prevalence by month of testing.  The total number of head tested each month 
was summed and prevalence calculated.   
 
Month Tested # of Lots # Head Tested # Head Positive Raw Prevalence % 
January 107 11,105 49 0.44 
February 158 16,294 63 0.39 
March 181 16,524 59 0.36 
April 127 9,810 26 0.27 
May 78 7,327 38 0.52 
June 52 5,771 12 0.21 
July 65 6,507 24 0.37 
August 53 6,466 16 0.25 
September 88 8,652 34 0.39 
October 227 26,783 56 0.21 
November 190 20,455 80 0.39 
December 154 16,398 65 0.40 
Total 1,480 152,092 522 0.34 
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Table 5.6.  Association between month of testing and PI-BVDV prevalence. 
 
Month Tested OR 95 % CI P-Value 
January 2.63 1.75  3.98 0.00 
February 2.38 1.60  3.53 0.00 
March 1.90 1.29  2.78 0.001 
April 1.38 0.85  2.24 0.20 
May 2.53 1.64  3.89 0.00 
June 1.02 0.54  1.93 0.94 
July 1.82 0.12  2.98 0.016 
August 1.31 0.74  2.34 0.352 
September 2.06 1.33  3.2 0.001 
October 1.00 NA NA 
November 2.06 1.34  2.79 0.000 
December 1.94 1.34  2.8 0.000 
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Table 5.7.  Prevalence based on operation 
 
Operation # of Lots # of Calves # of PI  Positive Raw Prevalence % 
Cow-Calf 209 11,116 42 0.38 
Stocker 198 16,085 88 0.55 
Feedlot 1,067 125,542 391 0.31 
Total 1,474 152,743 521 0.34 
 
 
 
Table 5.8.  Association between operation and PI-BVDV prevalence. 
.  
Operation OR 95 % CI P value 
Cow-Calf 1.33 0.94  1.88 0.11 
Stocker 2.11 1.65  2.69 0.00 
Feedlot 1.00 NA NA 
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Figure 5.1.   The longitudinal prevalence of all cattle tested regardless of weight. 
 
 
 
Figure 5.2.  The longitudinal average weight of cattle that tested PI-BVDV negative or 
positive. 
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Figure 5.3.  Prevalence of animals that tested postive by ACE by weight class.  
 
 
Figure 5.4.  Number of head tested by month during 2006  2008.   
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Figure 5.5. Prevalence of PI-BVDV by month of testing from 2006  2008.   
 
 
Figure 5.6.  The number of head tested and prevalence of PI individuals when the 
submitting client was identified as a cow-calf operator. 
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Figure 5.7.  The number of head tested and prevalence of PI individuals when the 
submitting client was identified as a stocker operator. 
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Figure 5.8.  The number of head tested and prevalence of PI individuals when the 
submitting client was identified as a feedlot operator. 
 
 
 
 
